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Abstract 
Elevated plasma lipoprotein(a) (Lp(a)) is the most prevalent heritable risk factor in the 
development of cardiovascular disease. The apolipoprotein(a) (apo(a)) component of Lp(a) is 
strongly implicated in the pathogenicity of Lp(a). It is hypothesized that the inflammatory 
potential of Lp(a)/apo(a) is mediated by the lysine binding ability of the apo(a) kringle IV10 
(KIV10) domain, along with its covalently bound oxidized phospholipid (oxPL). Using targeted 
mutagenesis, two novel null alleles for the LPA gene that generate non-secretable apo(a) 
species have been identified, resulting from amino acid substitutions in the KIV10 domain. A 
potential mechanism by which KIV10 oxPL modification is enriched was identified. Finally, 
RNA-Seq was utilized to demonstrate gene regulation in macrophage-like cells in response to 
the lysine binding function and covalent oxPL of the KIV10 domain. It was determined that the 
lysine binding ability and covalent oxPL of apo(a) KIV10 are both implicated in vascular cell 
inflammation and atherosclerosis. 
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Lay Summary 
In humans, fats and cholesterol are transported in the blood stream as components of 
particles called lipoproteins. A high level of one lipoprotein variety, lipoprotein(a) (Lp(a)), 
has been determined to be the single most prevalent heritable risk factor for developing 
cardiovascular diseases by contributing to the build-up of plaques within the arteries, or 
“atherosclerosis”. Lp(a) is very similar to the more commonly known low-density lipoprotein 
(LDL), which is typically considered the “bad” cholesterol (in comparison to high density 
lipoprotein (HDL), which is typically considered the “good” cholesterol). Lp(a) contains a 
protein component called apolipoprotein(a) (apo(a)), which distinguishes Lp(a) from LDL, 
and is thought to be responsible for the increased pathogenicity of Lp(a) in comparison to 
LDL. Apo(a) contains many sub-sections, or “domains”, that contribute in different ways to 
its characteristics. One domain, kringle IV sub-type 10 (KIV10), is thought to be particularly 
important for the harmful effects of Lp(a) in the blood stream. Here, we investigated the 
implications of the functions of the KIV10 domain, and the potential roles this domain may 
have in the development of atherosclerosis. The KIV10 domain is able to bind lysine, which 
allows apo(a) or Lp(a) to associate closely with cell surface proteins and other ligands. 
Additionally, the KIV10 domain is modified covalently with an oxidized phospholipid 
(oxPL). The lysine binding ability of KIV10 has been determined to have atherosclerosis-
related effects in certain vascular cell types, as have oxPLs. Together, this suggests that the 
KIV10 domain may represent an important factor in mediating the harmful effects of Lp(a) in 
the blood stream. We have determined that either of two independent amino acid 
substitutions in KIV10 can prevent the secretion of apo(a) entirely, and that a different 
substitution can change the amount of oxPL added to this domain. Beyond that, we have 
determined that the lysine binding ability and covalent oxPL of the KIV10 domain are 
implicated in many gene-regulatory processes that can potentially facilitate the development 
of atherosclerosis in humans. 
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Chapter 1  
1 Introduction 
1.1 Lipoprotein(a) 
1.1.1 Structure 
Lipoprotein(a) (Lp(a)) is a unique class of lipoprotein found only in humans, apes, and Old 
World Monkeys. Originally discovered in 1963 by Kåre Berg, Lp(a) is comprised of two 
fundamental components: a lipoprotein moiety virtually indistinguishable from low density 
lipoprotein (LDL), and a single molecule of apolipoprotein(a) (apo(a))1 (Figure 1.1). The 
LDL-like lipoprotein component contains a cholesteryl ester- and triglyceride-rich core, a free 
cholesterol/phospholipid monolayer outer shell, and a single copy of apolipoproteinB-100 
(apoB-100); in the case of Lp(a), apo(a) is bound covalently to apoB-100 via a single disulfide 
bond2. Under normal conditions, apo(a) maintains a lysine binding-dependent “closed” 
conformation in association with the apoB-100 component of Lp(a), which can be inhibited by 
the addition of the lysine analog -aminocaproic acid (-ACA) to produce a “ball-and-chain”-
type “open” conformation. This conformation can be visualized using electron microscopy to 
demonstrate both the single site of covalent linkage between apo(a) and apoB-100, as well as 
the “beads on a string” appearance of the kringle domains of apo(a)3 (Figure 1.2). 
The presence of apo(a) imparts unique properties and characteristics to Lp(a) that differ from 
those of LDL, largely owing to the presence and functions of multiple kringle domains in 
apo(a) that are highly homologous to plasminogen kringle 4 (KIV)4 (Figure 1.3). Beginning 
at the amino terminus, the KIV domains in apo(a) are classified into ten sub-types (KIV1 
through KIV10), each differing from the others based on the amino acid sequence and, in turn, 
dictating their characteristics and functions in the mature protein4. Each KIV subtype is present 
in apo(a) in a single copy with the exception of KIV2, which appears in a variable number of 
identical copies (from 3 to >35 in humans); the number of KIV2 domains is encoded at the 
genomic level by the LPA gene, giving rise to extensive heterogeneity in apo(a) isoform size 
in the human population2. Carboxyl-terminal to the KIV sequences, apo(a) contains single 
copies of kringle V- (KV) and protease-like domains, each highly homologous to the 
corresponding kringle 5 and protease domains of plasminogen. Unlike plasmin, the protease-
2 
 
like domain of apo(a) is enzymatically inactive5,6. The close homology between apo(a) and 
plasminogen contributes to the disruption of the balance between thrombosis and fibrinolysis, 
since apo(a) inhibits plasminogen activation in a number of contexts, resulting in prolonged 
blood clot breakdown5.  
Some specific functionalities relevant to the assembly and molecular pathology of Lp(a) are 
attributable to the lysine binding capabilities of certain KIV domains in apo(a). Low-affinity, 
or “weak” lysine binding sites (wLBS) are present in each of the KIV7 and KIV8 domains of 
apo(a). The functionality of these wLBS are required for initial non-covalent interactions with 
exposed lysine residues in the amino-terminal globular domain of apoB-100, thereby 
facilitating the first stage of assembly of the Lp(a) holoparticle6–9. This lysine binding-
dependent non-covalent association is followed by the formation of a single covalent disulfide 
bond between Cys4057 of apo(a)10, found in the KIV9 domain, and a still-debated cysteine 
residue in apoB-100. Guevara et al. demonstrated Cys3734 as the apoB-100 cysteine residue in 
question using molecular modelling and fluorescent labelling of potential candidate residues11, 
while Callow et al. posit that Cys4326 is the residue involved in disulfide bond formation with 
apo(a) as determined using mutagenesis12. 
Finally, the KIV10 domain of apo(a) possesses two characteristics that make it unique with 
respect to the other KIV domains, and of most relevance to this thesis: a high-affinity, “strong” 
lysine binding site (sLBS), and an amino acid residue to which an oxidized phospholipid 
(oxPL) is covalently bound13,14. The covalent oxPL modification of apo(a) has been determined 
empirically to absolutely require the functionality of the sLBS of KIV10 for addition. The 
proposed roles for the sLBS and covalent oxPL are described in in detail Section 1.1.6. 
In addition to the unique covalently-bound oxPL, Lp(a) has been shown to be the preferential 
carrier of oxPL in the plasma over LDL, an important factor in the context of inducing 
inflammatory phenotypes in vascular cells and subsequent development of cardiovascular 
pathologies15. 
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Figure 1.1. Schematic representation of the Lp(a) particle. 
Lp(a) is a unique lipoprotein owing to its inclusion of apolipoprotein(a). Sharing many 
characteristics with LDL, Lp(a) possesses a lipoprotein core comprised of triglycerides (TG) 
and cholesteryl esters (CE), surrounded by a monolayer of phospholipids (PL) and unesterified 
free cholesterol (FC), all associated with a single copy of apoB-100. In addition to its bulky 
lipoprotein core, Lp(a) possesses a single copy of apo(a) covalently bound to apoB-100 by a 
disulfide bridge involving the single free cysteine residue present in the apo(a) KIV9 domain. 
Apo(a) contains ten kringle domains homologous to plasminogen KIV, each present in a single 
copy with the exception of KIV2, which varies from 3 to >35 identical repeats corresponding 
to the number of KIV2 sequences encoded in the LPA gene, and determines the overall size of 
the apo(a) molecule. The specific characteristics and functions of the various kringle domains 
comprising apo(a) are described in Section 1.1.2. Also shown are oxidized phospholipids 
(OxPL) associated with the lipid core as well as covalently bound to KIV10. [Boffa & 
Koschinsky, 2019]. 
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Figure 1.2. Electron micrographs of LDL and Lp(a). 
LDL can be visualized using electron microscopy as (A) a tightly clustered lipoprotein particle, 
exhibiting regions of high electron density corresponding to its apoB-100 component. Lp(a) 
exhibits lysine-dependent interactions between apo(a) and apoB-100, similarly yielding (B) a 
tightly clustered lipoprotein particle with more electron-dense regions compared with LDL due 
to the presence of apo(a), or (C) as an “open” conformation with a “ball-and-chain” appearance 
upon the addition of the lysine analog -ACA. In the open conformation, individual kringle 
domains of apo(a) can be visualized as “beads on a string” (red arrows), and the single covalent 
bond involving KIV9 near the C-terminus of apo(a) can be inferred (green arrow). [Weisel et 
al., 2001]. 
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Figure 1.3. Schematic representation of apo(a). 
Apo(a) strongly resembles plasminogen, sharing substantial sequence and structural 
homology. Both apo(a) and plasminogen contain multiple kringle domains; the kringles that 
make up apo(a) include ten unique subtypes sharing extensive sequence identity with 
plasminogen K4 (KIV1-KIV10), each found in a single copy with the exception of KIV2, which 
is a repeating domain ranging from 3 to >35 identical copies. In addition to its KIV domains, 
apo(a) also possesses domains similar in sequence to the plasminogen K5 and protease 
domains; in apo(a), the protease domain is not enzymatically active. Apo(a) lacks sequences 
corresponding to the plasminogen tail, K1, K2, and K3 domains. Certain apo(a) KIV domains 
possess characteristics that are important for the assembly and pathogenicity of Lp(a): the weak 
lysine binding sites found in KIV7 and KIV8 are essential for initial non-covalent interaction 
between apo(a) and apoB-100, the unpaired Cys4057 found in KIV9 is required for covalent 
linkage to apoB-100, and KIV10 contains both a strong lysine binding site (strong LBS) as well 
as a covalently-bound oxPL. Full function of the strong lysine binding site found in KIV10 is 
necessary for covalent oxPL modification to occur. [Boffa & Koschinsky, 2019]. 
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1.1.2 Apolipoprotein(a) 
Apo(a) distinguishes Lp(a) from LDL both structurally and functionally, imparting Lp(a) with 
unique characteristics. Apo(a) is approximately 28% carbohydrate by weight16. As previously 
stated, apo(a) is composed of repeating domains homologous to the KIV domain of 
plasminogen. In fact, it has been determined that the existence of LPA in humans, apes, and 
Old World Monkeys, is the result of a gene duplication of PLG, and that gene divergence of 
what we now know as LPA and its parent gene PLG occurred relatively recently during primate 
evolution (approximately 40 million years ago)4,17. The kringle domains found in apo(a) and 
plasminogen are so named for their physical resemblance to a traditional Danish pastry of the 
same name. Kringles form a characteristic tri-looped structure composed of about 80 amino 
acids, wherein three invariant disulfide bonds are formed between the six invariant cysteine 
residues present in each kringle (Figure 1.4). KIV9 is the only domain possessing a seventh 
cysteine; nascently unpaired, this cysteine is the residue through which apo(a) links covalently 
to apoB-100 in the covalent assembly of the Lp(a) holoparticle10. Between each apo(a) kringle 
domain, there is an inter-kringle linker region of approximately 30 amino acids, rich in serine 
and threonine residues and thus representing the major proposed sites of O-linked 
glycosylation18. Each KIV domain also possesses at least one site for N-linked glycosylation19. 
Kringle domains are largely considered to serve as protein-binding domains, suggesting that 
the presence of apo(a) on Lp(a) allows interactions with a variety of ligands with which LDL 
is unable to interact.  
Due to its KIV10 lysine-binding sites and covalently bound oxPL, it has been hypothesized that 
apo(a) confers pathogenic potential to Lp(a) beyond that which can be attributed to LDL. The 
lysine-binding ability of apo(a) allows it to bind exposed lysine residues on a wide variety of 
ligands, including fibrin and cell-surface receptors20–22. The previously mentioned zymogen, 
plasminogen, also bears lysine-binding kringle domains, the binding interactions of which 
facilitate its cleavage and activation to the fibrinolytic enzyme plasmin which, in turn, 
promotes the dissolution of fibrin clots23,24. The presence of apo(a) on Lp(a) slows the action 
of plasmin by inhibiting plasminogen cleavage in a number of contexts25,26, thereby evoking a 
net anti-fibrinolytic/pro-thrombotic effect. A second mechanism by which apo(a) slows the 
action of plasmin has been demonstrated as well: apo(a) has been shown to participate in the 
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formation of a plasminogen-tissue plasminogen activator (tPA)-fibrin-apo(a) complex which 
exhibits a reduced rate of plasmin activation compared with the same complex lacking apo(a)5.  
The covalently bound oxPL of KIV10 is implicated in stimulating the production of a variety 
of pathogenic stimuli, as oxidized lipids have been shown to induce inflammatory processes 
in vascular cell types14,27–30. Plasma oxPL/apoB-100 ratio has a strong correlation with Lp(a) 
concentration in humans, and further, oxPL/apoB-100 has been found to correlate with the 
presence and extent of coronary artery disease (CAD)31,32. Elevated oxPL/apoB-100 has also 
been shown to correlate with prevalence of carotid and femoral artery diseases33. The covalent 
oxPL moiety of apo(a) has been shown to induce apoptosis in endoplasmic reticulum (ER)-
stressed macrophages in a CD36- and toll-like receptor 2 (TLR2)-dependent manner34, a key 
step in the formation of the necrotic core in atherosclerotic lesions. Based on this information, 
a strong role for apo(a), and Lp(a) by extension, is suggested in the initiation of endothelial 
dysfunction, vascular cell inflammation, and necrotic core formation – key processes in the 
initiation and progression of atherosclerosis. 
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Figure 1.4. Crystal structure of KIV10. 
Kringle domains are found in both plasminogen and apo(a), as well as other proteins involved 
in thrombotic and fibrinolytic processes. Kringle domains possess a hallmark tri-looped 
structure stabilized by three invariant disulfide linkages, shown in yellow. Kringles represent 
important domains for protein-ligand interactions; KIV10 possesses a strong lysine binding site 
which facilitates interactions between apo(a) and fibrin, cell surface receptors, and other 
ligands. The lysine analog -ACA is shown as the bound ligand. Two aspartic acid residues 
(red) and one tryptophan residue (magenta) that are crucial to the function of the sLBS are 
shown. Figure generated using PyMOL version 2.3.2, pdb: 3KIV, produced by Mochalkin et 
al.35. 
 
 
 
 
9 
 
1.1.3 Lp(a) metabolism 
1.1.3.1 Apo(a) secretion 
Up to 90% of the variability seen in human plasma Lp(a) concentrations can be attributed to 
LPA36, the gene encoding apo(a), which is found on human chromosome 6q25.3-q264. The size 
of the LPA gene itself varies widely within the population, reflecting differences in the number 
of KIV2-encoding sequences present. In general, an inverse correlation exists between the 
isoform size encoded by a given LPA allele and the corresponding plasma Lp(a) concentration 
observed7,37. It is believed that more time is required for cells to process larger apo(a) isoforms 
due to the greater total number of kringles present, the complex folding required for each, and 
extensive post-translational modification in the form of N- and O-linked glycosylation. This 
extended processing stage results in longer periods of ER retention and subsequent ER-
associated degradation, the end result of which is reduced levels of secreted protein species 
and circulating Lp(a)38–40. In light of this, it is important to note that Lp(a) levels are generally 
agreed to be determined primarily at the level of what can broadly be termed “production”, 
rather than uptake and catabolism of the particle from circulation. In vivo kinetic studies in 
humans have ascribed differences in apo(a) production rates for different isoform sizes 
(slowest production rates for largest isoform sizes), while failing to show such a relationship 
for fractional catabolic rates41. 
Biosynthesis of Lp(a) begins in a similar fashion to many secreted proteins: transcription of 
the gene, in this case LPA, and subsequent apo(a) protein translation/ER translocation, 
processing, and passage through the constitutive secretory pathway. Several transcription-
regulating elements have been identified for LPA, including an inductive interleukin (IL)-6 
response element in the LPA promoter region42, a repressive DR-1 promoter element which is 
bound by the bile acid-bound farnesoid X receptor (FXR)43, an Ets motif that has been shown 
to mediate repression of LPA transcription by fibroblast growth factor 19 (FGF-19) via Elk-1 
binding44, and several cAMP response elements thought to play a role in niacin-mediated Lp(a) 
reduction45. However, the transcriptional control of LPA is not fully understood, with evidence 
suggesting a gene-repressing role for estrogens based on studies in men undergoing estrogen 
therapy for prostate cancer46, as well as post-menopausal women receiving estrogen 
replacement47. Finally, apo(a) secretion is intrinsically regulated by intracellular processing 
requirements according to the isoform size in question. The proportionally increased ER 
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retention time observed in apo(a) isoforms of increasing size results in increased proteasomal 
degradation and, accordingly, reduced secretion efficiency39. 
With respect to apo(a) secretion, the importance of the processes underlying general protein 
processing and quality control must be considered thoroughly. Classically, the process of 
protein secretion involves unidirectional movement of proteins of interest through the ER, the 
Golgi apparatus, secretory vesicles, and finally culminates in their extracellular release. At the 
same time, quality control processes typically ensure only properly folded proteins are 
secreted, targeting misfolded proteins for degradation. Most secreted proteins possess an N-
terminal signal sequence that is recognized by cytosolic targeting factors and ER-resident 
translocation machinery48, which directs the translation of that protein/peptide to occur through 
an ER-embedded Sec61 pore complex following association with the cytosolic ER 
membrane49. The signal recognition particle, a multimeric complex comprised of both protein 
and RNA components50, mediates the targeting of signal peptide-containing polypeptides to 
the ER, whilst simultaneously slowing protein translation to prevent premature cytoplasmic 
protein folding that would preclude ER translocation51. The N-terminal end of the nascent 
polypeptide is first inserted into the ER, where a protease complex, usually signal peptidase, 
cleaves the signal peptide52. Protein translation directly into the lumen of the ER then follows, 
and ER-based quality control of protein folding and post-translational modification occurs. 
During translation of the protein into the lumen of the ER, sequence recognition by the 
oligosaccharyltransferase complex occurs, during which N-linked Glc3Man9GlcNAc2 glycan 
motifs are added to Asn in the Asn-X-Thr/Ser consensus sequence53; as mentioned previously, 
each kringle domain of apo(a) possesses at least one such N-glycan attachment site, making 
this ER-localized stage of protein modification important in the processing of apo(a). It has 
been demonstrated that the addition and trimming of N-linked glycans is important for the 
subsequent folding of a great number of secreted protein species, including apo(a)39,54,55. This 
folding process is facilitated by a number of catalytic isomerases (e.g. protein disulfide 
isomerase), glycosidases, molecular chaperones (e.g. calnexin), and by the oxidizing 
environment of the ER which favors disulfide bond formation. In the case of properly folded 
and modified proteins, normal progression to the Golgi apparatus occurs by way of COPII-
coated vesicular budding56,57. However, in cases of misfolded or improperly processed 
proteins, the constitutively active ER-associated degradation (ERAD) pathway selectively 
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recognizes these proteins and exports them for cytosolic degradation by the proteasome58–60, 
blocking their passage to the Golgi. 
With respect to the processing and secretion of apo(a), three key studies in cultured baboon 
hepatocytes are particularly relevant in the context of this thesis. First, a radioactive pulse-
chase study revealed that two distinct sizes of apo(a) could be isolated simultaneously from 
cell lysates: both a mature, glycosylated form of apo(a) and an immature hypo-glycosylated 
form of apo(a). It is crucial to note that only the mature, fully glycosylated form of the protein 
was secreted by the cell61. The second study revealed that tunicamycin, an indirect inhibitor of 
N-linked glycosylation, prevented the maturation and secretion of apo(a), and that 
castanospermine, an inhibitor of N-linked glycan trimming, produced a similar effect39. It 
should be noted that this effect was not observed previously in HEK293 cells stably expressing 
apo(a)62. A third study identified variants of apo(a) that could be isolated from cell lysates but 
were not secreted; it was determined using immunoprecipitation coupled with pulse-chase 
analysis and endoglycosidase digests that these apo(a) species were being retained in the ER40. 
Taken together, these data strongly indicate that proper folding as well as N-linked 
glycosylation are both critical for the secretion of apo(a). 
1.1.3.2 Lp(a) assembly 
Biosynthesis of Lp(a) not only encompasses apo(a) secretion, but also the assembly of the 
particle, first by initial lysine-dependent non-covalent interaction between apo(a) and apoB-
100, and followed by the covalent linkage of apo(a) to apoB-100 (Figure 1.5). Until recently, 
it has been generally accepted that Lp(a) assembly occurs exclusively extracellularly, from 
newly-secreted apo(a) and either newly-synthesized or circulating LDL; in both cases, the 
secretion of the apoB-100-containing species is proposed to be unlinked to that of apo(a). This 
model for Lp(a) assembly has come under scrutiny after an in vivo kinetic study in humans 
showed that the production rate of Lp(a)-associated apoB-100 is quite different than the 
production rate of apoB-100 found in other lipoprotein species, but matches very closely with 
the production rate of apo(a)63, suggesting a yet uncharacterized relationship between the 
secretion of apo(a) and Lp(a)-apoB-100. These findings indicate the possibility of intracellular 
Lp(a) assembly, but the existence of an Lp(a)-destined apoB-100-containing lipoprotein pool 
must also be considered as a possibility. Regardless of the location of initial noncovalent 
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interaction, an in vitro model of Lp(a) assembly has demonstrated the extracellular activity of 
an Lp(a)-specific oxidase enzyme involved in catalyzing the formation of the covalent bond 
between Cys4057 of apo(a) and Cys3734 or Cys4326 of apoB-10064. However, the identity of this 
enzyme and its mechanism of action have not been fully determined. When hypothesizing 
about the secretion and assembly processes that comprise Lp(a) formation, we must also 
consider the fact that many therapies known to reduce circulating LDL levels (e.g. 
mipomersen, lomitapide, anacetrapib, and proprotein convertase subtilisin/kexin type 9 
(PCSK9) inhibitors) also reduce Lp(a) levels65–70. While much is still unknown about the 
specifics of Lp(a) assembly in the context of apo(a) secretion and its relationship with apoB-
100, it is known that free apo(a) is not simply secreted into the plasma prior to association with 
an LDL particle; it has been demonstrated that apo(a) species with nonsense mutations N-
terminal to Cys4057 (and thereby lacking the ability to form the covalent link to apoB-100 
required for Lp(a) assembly) experience rapid degradation in the plasma71. Free apo(a) is 
detectable at very low levels in the plasma, but the vast majority is present in Lp(a) particles72. 
1.1.3.3 Catabolism 
Further complicating our incomplete understanding of Lp(a) metabolism, a robust 
understanding of Lp(a) catabolism remains elusive. Although no definitive receptor for Lp(a) 
has been identified, it has been established that the liver is the organ for Lp(a) catabolism, 
while also representing the dominant source of apo(a) secretion. Roles in Lp(a) internalization 
have been described for a number of receptors including the following: the LDL receptor 
(LDLR)73,74 and LDLR family (very low density lipoprotein receptor (VLDLR), LDLR-related 
protein 1, and gp330/megalin)75–77, the plasminogen receptor family (PLG-RKT)78, and 
scavenger receptor superfamily (scavenger receptor B1)79. The relative contribution of each 
receptor type to the overall internalization and catabolism of Lp(a) has not been determined. 
The kidney has also been identified as a minor potential contributor to Lp(a) catabolism owing 
to its expression of the VLDLR and/or gp330/megalin80, but no renal Lp(a) uptake studies have 
been performed in humans to date. 
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Figure 1.5. Proposed two-step model for Lp(a) formation. 
The current understanding of Lp(a) formation involves a two-step mechanism. In the first step, 
apo(a) associates non-covalently with free lysine residues in the N-terminal globular domain 
of apoB-100 via weak lysine binding sites in the apo(a) KIV7 and KIV8 domains. The precise 
location of initial non-covalent interaction between the two species is unclear; evidence has 
been presented to suggest that both intracellular and extracellular association are possible. 
Additionally, it has been demonstrated that the rate of Lp(a)-apoB-100 secretion closely 
matches that of apo(a). Regardless of the location of this interaction, it has been shown that it 
can be competitively inhibited with the addition of lysine analogs such as -ACA. The second 
step of Lp(a) assembly is the formation of a single disulfide bond between Cys4057 of apo(a) 
and either Cys3734 or Cys4326 (current findings indeterminate)11,12 of apoB-100. This bond 
formation is catalyzed by an extracellular Lp(a)-specific oxidase. [Becker et al., 2006]. 
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1.1.4 Determinants of plasma Lp(a) concentration 
Plasma concentrations of Lp(a) vary widely within the population, from levels that are 
undetectable to those in excess of 250 nanomolar. It is well established that plasma Lp(a) 
concentrations are determined predominantly at the stage of production, and that there is a 
general inverse relationship between concentration of Lp(a) and the size of the LPA gene 
encoding apo(a). The determinants that collectively dictate the level of Lp(a) in the plasma are 
LPA transcription, apo(a) secretion, assembly of Lp(a), and its catabolism.  
While LPA gene size is the major genetic determinant of apo(a) production and Lp(a) 
concentration, the general inverse relationship between the two only accounts for about 70% 
of the observed variation in plasma Lp(a) concentrations. Approximately 22% of this variation 
has been attributed to cis-acting sequences in the gene whose influences have not been fully 
characterized36. There is evidence to suggest that the size of a given LPA allele affects not only 
the plasma concentration of Lp(a) with the corresponding isoform, but that of the second 
isoform as well81,82. Furthermore, there is evidence that single nucleotide polymorphisms 
(SNPs) influence plasma Lp(a) concentrations as well: rs3798220 (protease-like domain, 
Ile4399→Met) and rs10455872 (KIV2, intronic) are associated with elevated Lp(a) levels and 
increased incidence of CVD83. 
At the genomic level, several transcription factor binding sites in the LPA promoter region 
have been identified as modulators of gene transcription. As mentioned previously, these 
elements include those responsive to 1) IL-6, with a 5-fold enhancement in LPA reporter gene 
activity reported in HepG2 cells treated with IL-642, 2) bile acids, repressing LPA transcription 
via an FXR response element43, 3) FGF-19, down-regulating transcription via Elk-1 binding 
to an Ets motif44, and 4) cAMP, up-regulating expression (but depleted by niacin)45. In addition 
to these factors, exogenous estrogen supplementation has been shown to reduce Lp(a) 
levels46,47. However, the exact role of estrogens in this context remains elusive when one 
considers that there is no significant difference between plasma Lp(a) levels in healthy men 
and pre-menopausal women, despite a great discrepancy in concentrations of circulating 
estrogens84. Further, it has been demonstrated that Lp(a) levels are higher in post-menopausal 
women than in pre- or peri-menopausal women, indicating further differences in the handling 
of Lp(a) in males and females85. 
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Interestingly, it has also been established that a given LPA allele may be associated with 
considerably different concentrations of Lp(a) in the plasma, especially between individuals of 
different ethnic backgrounds; multiple studies have shown that African Americans have 
median plasma Lp(a) concentrations significantly exceeding that of Caucasians, and that this 
discrepancy is not fully accounted for by differences in isoform size distribution81,86,87. 
1.1.4.1 “Null” LPA alleles 
Only two null alleles of the LPA gene have been identified in humans – both of which result 
in the generation and secretion of apo(a) species that are unable to participate in Lp(a) 
assembly. As discussed previously, it has been shown that such unbound apo(a) species are 
degraded rapidly. A splice site mutation (rs41272114) results in the production of an 
alternately-spliced LPA transcript, the translation of which generates an apo(a) variant that is 
truncated after KIV7 and prevents both non-covalent and covalent associations with apoB-
10071. This SNP is associated with reduced plasma Lp(a) concentrations and reduced CAD 
risk88. The other null allele (rs# unclear, “G4925A”89) produces a nonsense mutation in the 
KIV2 region; this apo(a) species is believed to be secreted, but, once again, is unable to form 
Lp(a) and subsequently results in reduced plasma Lp(a) levels90. While these two null alleles 
are the only confirmed variants of this nature, recent findings suggest the discovery of novel 
non-synonymous mutations in LPA that represent null alleles for apo(a), by causing the 
intracellular retention and degradation of the encoded apo(a) species (unpublished data 
presented at European Atherosclerosis Society 87th Congress by S McCormick, Maastricht, 
The Netherlands, 2019). 
1.1.5 Cardiovascular disease and atherosclerosis 
Cardiovascular disease (CVD) is a broad term referring to a class of diseases characterized by 
dysfunction of the heart and/or vasculature, and collectively represents the leading cause of 
death in the developed world91. While CVD encompasses many specific types of pathologies, 
the most common is CAD, accounting for the greatest burden of mortality and morbidity of 
any CVD subtype92. CAD is a progressive disease, believed to be initiated by the exposure of 
the arterial endothelial lining to some form of insult. As a result, endothelial cells undergo 
structural changes that compromise the integrity of tight junctions between them, increasing 
the permeability of the lining to circulating particles and allowing the accumulation of 
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lipoproteins and leukocytes, among other blood components, within the intimal compartment 
of the vessel93. The initial insult to the vessel may take the form of chronically elevated 
circulating lipids (dyslipidemias), exposure to compounds found in cigarette smoke, shear 
stress, hyperglycemia, obesity, hypertension, or insulin resistance94. Each of the 
aforementioned insults results in activation of signaling pathways that lead to the generation 
of excess reactive oxygen species (ROS) and subsequently, an environment within the 
endothelial cells characterized by high levels of oxidative stress95,96. High intracellular levels 
of oxidative stress activate the NF-B pathway, and in turn induce the expression of genes 
under the control of NF-B-response elements95,96. NF-B-inducible genes encode protein 
products that serve a wide range of functions including cell surface adhesion molecules (e.g. 
E- and P-selectins, intercellular adhesion molecule 1 (ICAM-1), and vascular cell adhesion 
molecule 1 (VCAM-1))97–100 and pro-inflammatory cytokines (e.g. interferon- (IFN-), IL-
1/, 6, and 8, tumor necrosis factor  (TNF), and monocyte chemoattractant protein 1 
(MCP-1))101–106, among others. 
Following initial insult and ROS-induced NF-B signaling, vascular endothelial cells undergo 
phenotypic changes, resulting in what can broadly be termed “endothelial dysfunction”. 
Endothelial dysfunction compromises the integrity of intercellular tight junctions, allowing the 
aberrant efflux of pathogenic factors such as LDL and Lp(a) from the lumen of the vessel into 
the intimal (sub-endothelial) layer of the vessel wall. It should be noted that upon entering the 
intimal space of the vessel wall, lipoproteins may be acted upon by enzymes or encounter 
oxygen radicals, leading to their oxidative modification107; the exposure of endothelial cells to 
oxidized lipoproteins promotes the adhesion and extravasation of immune cell types from the 
plasma by inducing further production of cell adhesion molecules29,108,109 and secretion of pro-
inflammatory factors110. Pro-inflammatory cytokines secreted by the damaged endothelial 
lining serve to further immune cell convergence and invasion at the site of injury, thereby 
initiating and propagating a local inflammatory response, initiating the process of 
atherosclerotic plaque formation111,112.  
Following the initiation phase resultant from endothelial dysfunction, intimal invasion by 
immune cells such as monocytes becomes a primary factor in the advancement of local 
inflammation and atherosclerotic lesion development. Upon their arrival in the intimal space, 
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monocytes encounter high levels of stimulating growth factors including macrophage colony 
stimulating factor (M-CSF) and granulocyte-macrophage colony stimulating factor (GM-
CSF), inducing their differentiation and maturation to macrophages113,114. In vitro, M-CSF is 
constitutively expressed under basal conditions by endothelial cells and smooth muscle cells 
(SMCs), as well as fibroblasts115,116. On the other hand, GM-CSF expression is inducible in 
vitro by TNF and IL-1 in arterial SMCs114, and by oxidized LDL (oxLDL) in endothelial 
cells and macrophages in vivo117. This suggests a mechanism by which leukocyte 
chemoattratants contribute to the propagation of the chronic and non-resolving inflammatory 
processes ongoing in the developing lesion. As monocyte-to-macrophage differentiation 
occurs, so too does the up-regulation of TLRs and scavenger receptors in these cells, mediating 
cell signaling processes that lead to inflammatory cytokine secretion and lipid uptake118,119. 
Macrophages in the intimal space bind and engulf oxLDL and oxidized Lp(a) via pattern 
recognition receptors including the TLRs and scavenger receptors mentioned previously, along 
with CD36. Macrophage uptake of oxidized lipids leads to the formation of lipid-laden foam 
cells and stimulates their secretion of pro-inflammatory factors119–122. These factors propagate 
further inflammatory responses in vascular cell types while continued uptake of lipoproteins 
triggers ER stress-mediated apoptotic processes in foam cells, and lead to the formation of the 
necrotic core in the atherosclerotic plaque34,123. In addition to the aforementioned processes, 
cytokines secreted by activated macrophages induce local migration and proliferation of 
SMCs111 and contribute to downstream platelet aggregation124; stimulation of both endothelial 
cell and SMC contraction, migration, and proliferation has also been observed in direct 
response to apo(a) exposure in an V3 integrin- and RhoA/Rho kinase-dependent 
fashion125,126. Platelet aggregation and subsequent activation, mediated by blood-borne von 
Willebrand factor, promotes the secretion of platelet-derived growth factor (PDGF) and 
transforming growth factor  (TGF-), propagating SMC migration and proliferation, as well 
as synthesis and secretion of extracellular matrix (ECM) components by SMCs, 
respectively127–130. The combination of SMC proliferation and migration, coupled with ECM 
deposition, leads to the formation of the lesion’s fibrous cap131, while the contractile response 
of SMCs to Lp(a) exposure is thought to reduce plaque stability. Overall, the summation of 
these processes represents the cyclic nature of both the formation as well as the progression of 
atherosclerotic plaques. 
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As the deposition of arterial plaques continues over the span of years to decades, blood vessel 
occlusion gradually obstructs blood flow. In the case of plaque formation in the coronary 
arteries, (i.e. CAD), blood flow to the myocardium itself becomes reduced and presents 
symptomatically with feelings of tightness or pain in the chest, clinically termed angina132. 
Over time, chronic exposure of macrophages, endothelial cells, and SMCs to inflammatory 
factors such as TNF and decreased nitric oxide levels promotes their secretion of collagenases 
and matrix metalloproteinases (MMPs)133,134. Without intervention, the plaque continues to 
grow and the stability of the fibrous cap may be compromised by MMP-mediated ECM 
degradation, reducing the overall stability of the plaque and increasing its risk of rupture. If 
plaque rupture occurs, exposure of blood to the components of the plaque precipitates the 
formation of a thrombus which may occlude coronary artery flow completely, resulting in 
ischemia of the myocardium and subsequent myocardial infarction131. Plaque rupture in other 
vessels can lead to other major events such as ischemic stroke. Recalling the anti-fibrinolytic 
effect of Lp(a)/apo(a) as an inhibitor of plasmin formation discussed briefly in Section 1.1.2, 
it is reasonable to speculate that plasma Lp(a) concentration may be a contributing factor in 
determining the prevalence and severity of cardiovascular events following plaque rupture. 
1.1.6 Pathophysiology of Lp(a) 
The structural duality of the Lp(a) particle, containing both an LDL-like bulky lipid moiety 
and a plasminogen-like apo(a) molecule, suggests that Lp(a) may participate in both 
atherogenic and anti-fibrinolytic processes in the vasculature. The potential effects of the 
KIV10 sLBS and covalent oxPL on macrophages, endothelial cells, and SMCs are summarized 
in Figure 1.6. 
1.1.6.1 Oxidized phospholipid modification of Lp(a) 
Oxidized lipoproteins are important drivers of the inflammatory processes involved in the 
progression of atherosclerosis. In this context, the determination that Lp(a) is the preferential 
carrier of oxPL in the plasma, compared to LDL, becomes even more relevant. In a study of 
all lipoprotein-associated oxPL, it was determined that Lp(a) was found to contain 
approximately 85% of the total quantified oxPL135. In fact, it has even been shown in vitro that 
preferential oxPL enrichment of Lp(a), compared to LDL, increases upon oxLDL incubation, 
suggesting oxPL transfer from oxLDL to Lp(a)15. While both LDL and Lp(a) contain non-
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covalently associated oxPL, Lp(a) is unique in that it also contains a covalently-bound oxPL. 
Originally believed to be present within the KV domain136, it has since been determined that 
the oxPL is covalently attached within the apo(a) KIV10 domain13. Interestingly, as discussed 
previously, this domain also contains a sLBS. The proximity of these two unique features has 
led to speculation that the sLBS, known to mediate the interaction of Lp(a) with a variety of 
ligands, may also serve to bring the covalent oxPL in close proximity to these ligands and, in 
doing so, facilitate the pro-inflammatory and/or oxidative effects associated with exposure to 
oxPLs. The role of oxPLs in the facilitation of inflammatory processes in the context of 
atherosclerosis is well understood: it has been shown that exposure of leukocytes to oxPLs 
activates a variety of pro-inflammatory responses, namely the secretion of pro-
inflammatory/chemoattractant cytokines, and macrophage apoptosis137,138. OxPLs have been 
shown to induce transcription of CXCL8 and secretion of its cytokine product, IL-8, as well as 
MCP-1 in endothelial cells in vitro139. Strong evidence for the role of oxPLs in the development 
of atherosclerosis in vivo was published recently, showing that mice overexpressing a single 
chain variable fragment transgene of the anti-oxPL E06 IgM (E06-scFv) exhibited significantly 
slower progression of atherosclerosis compared with non-transgenic mice on an identical high 
cholesterol diet140.  
With respect to Lp(a) and apo(a), it has been shown that Lp(a)/apo(a) induce apoptosis in ER-
stressed macrophages in an oxPL-dependent manner through the TLR2-CD36 heterodimer; 
removal of the covalent oxPL from apo(a) with phospholipase A2 (PLA2) destroyed its ability 
to exert pro-apoptotic effects in this study34. Furthermore, it has been shown that THP-1 
macrophages increase transcription of CXCL8 and secretion of IL-8 in response to apo(a) 
exposure, and that these effects are greatly diminished by PLA2-mediated oxPL removal14.  
Taken together, these data strongly implicate a role for Lp(a)/apo(a)-bound oxPL in the 
induction and propagation of vascular inflammation, the promotion of macrophage/foam cell 
apoptosis, and the overall development of atherosclerosis. 
1.1.6.2 Functional significance of the lysine binding properties of 
apo(a) KIV10 
Apo(a) has been shown in vitro to stimulate the RhoA/Rho kinase signaling cascade in 
endothelial cells, dependent on the presence of the KIV10 sLBS141. The result of this signaling 
20 
 
pathway is increased stress fiber formation, endothelial cell contraction, and increased 
permeability of the vessel wall. Also through the RhoA/Rho kinase pathway, apo(a) has been 
demonstrated to stimulate vascular SMC migration, proliferation, and chemorepulsion125,142. 
Additionally, the lysine binding activity of apo(a) has been implicated in vitro in the disruption 
of VE-cadherin/-catenin complexes, increased nuclear -catenin translocation, and the 
subsequent stimulation of prostaglandin synthesis through cyclooxygenase 2 (COX-2) up-
regulation in human umbilical vein endothelial cells (HUVECs)110. Lastly, it has been shown 
that apo(a) can inhibit tPA-mediated plasminogen cleavage on the cell surface of endothelial 
cells, monocytes, and macrophages in vitro26, and within fibrin clots5,143. The cell-surface 
effect was found to be related to the sLBS function of KIV10, and was diminished with the 
addition of the lysine analog -ACA, strongly indicating a role for the lysine-binding properties 
of apo(a) in the context of inhibiting plasmin activation. 
1.1.6.3 The role of Lp(a) in thrombosis and fibrinolysis 
A growing body of evidence from in vitro studies indicates pro-thrombotic/anti-fibrinolytic 
roles for Lp(a) and apo(a). The striking homology between apo(a) and plasminogen coupled 
with the lack of apo(a) protease activity suggests a role for apo(a) as an anti-fibrinolytic factor, 
owing to its ability to act as a inhibitor of plasmin activation by preventing the binding of 
plasminogen to surface receptors on endothelial cells and monocytes, and by inhibiting tPA-
mediated plasminogen cleavage on the cell surface26. Apo(a) slows plasmin formation by 
inhibiting the conversion of Glu1-plasminogen to the more readily activated Lys77-
plasminogen, thereby inhibiting the feed-forward mechanism by which maximal plasmin 
activation is achieved143,144. In addition to the sLBS function of KIV10, this process also 
requires sequences within the KIV5-8 and KV domains of apo(a)145,146. The apo(a) component 
of Lp(a) has also been shown to participate in the formation of a plasminogen-tPA-fibrin-
apo(a) complex, which exhibits a reduced rate of plasmin activation when compared with the 
same complex lacking apo(a)5. Inhibition of tPA-mediated plasmin activation by apo(a) has 
also been shown to slow thrombolysis in vivo, using both transgenic apo(a) mouse and rabbit 
jugular vein fibrinolysis models147,148. Beyond the inhibition of plasminogen cleavage by 
apo(a), Lp(a) has also been shown to increase synthesis of plasminogen activation inhibitors 
by endothelial cells and monocytes in vitro, providing another mechanism by which Lp(a) can 
indirectly inhibit plasmin formation149,150.  
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Finally, Lp(a) has also been implicated as a pro-thrombotic contributor due to its ability to bind 
tissue factor pathway inhibitor (TFPI), suppressing the anti-coagulant effects that TFPI 
normally exerts as a result upon binding to Factor Xa and the tissue factor/Factor VIIa 
complex151. As TFPI normally acts as a potent inhibitor of the tissue factor-initiated 
coagulation cascade, binding and inhibition of TFPI by Lp(a) supports a role for Lp(a) as a 
pro-thrombotic factor in hemostasis. 
Taken together, these data along with those presented in Sections 1.1.6.1 and 1.1.6.2 strongly 
implicate mechanistic roles for Lp(a)/apo(a) in both inflammatory and pro-thrombotic 
processes, but there remains debate as to the role of elevated Lp(a) concentrations in 
thrombosis and fibrinolysis in vivo152. 
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Figure 1.6. Effects of Lp(a)/apo(a) on vascular cell phenotypes. 
The deleterious effects of Lp(a) and/or apo(a) on a variety of vascular cell types are well 
documented. These effects importantly include increasing the secretion of IL-8 via NF-B 
signaling in macrophages, increasing contraction, migration, and proliferation in smooth 
muscle cells dependent on V3 integrin and RhoA/Rho kinase signaling, and increasing 
prostaglandin synthesis in endothelial cells downstream of a sLBS-dependent increase in 
nuclear translocation of -catenin and subsequent COX-2 up-regulation. TLR2, toll-like 
receptor 2; RhoA, Ras homolog gene family, member A; COX-2, prostaglandin-
endoperoxidase synthase 2. Figure created with Biorender.com. 
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1.1.7 Lp(a) as a risk factor for CVD 
Since its discovery over half a century ago, assessing the role of Lp(a) in the development of 
CVD in vivo remains a daunting challenge. The LPA gene, and therefore Lp(a) itself, exists 
only in humans, apes, and Old World Monkeys. As such, the in vivo study of Lp(a) is severely 
hindered by the unavailability of relevant animal models in determining the role of elevated 
Lp(a) in CVD. For example, to study Lp(a) in a murine model of disease, mice must 1) be 
transgenic for human apo(a), 2) produce human apoB-100 as opposed to murine apoB-48, and 
3) be bred onto an atherogenic background i.e. Ldlr-/- or Apoe-/-.  
Assessment of a 58,000-subject meta-analysis of 40 studies showed that individuals with <22 
total KIV repeats exhibited increased CAD risk in excess of 2-fold compared to individuals 
with >22 KIV153; the effect of apo(a) isoform size itself on pathogenicity has not been 
definitively resolved. It is difficult to assess whether these findings are a true representation of 
the effects of apo(a) isoform size rather than Lp(a) concentration, as many of the studies 
involved in this meta-analysis did not control for Lp(a) concentration. While studies such as 
this have reported Lp(a) as a risk factor for CVD for decades, distinguishing Lp(a) as a causal 
risk factor versus a disease marker had not been possible due to the study designs utilized. A 
Mendelian randomization study in 2009 confirmed the inverse relationship between LPA gene 
size and Lp(a) plasma levels, and also established a causal role for such “genetically elevated” 
Lp(a) concentrations in the incidence of CVD154. Since then, genome-wide association studies 
have also determined LPA gene size to be a major determinant of CVD risk155,156, and other 
genetic studies have associated two SNPs in the LPA gene with increased plasma Lp(a) 
concentration as well as increased CVD risk83. Further genetic studies have allowed us to draw 
a causal relationship between elevated plasma Lp(a) levels (>50 mg/dL) and >2-fold increased 
risk for CAD, and indeed that approximately 20% of the global population falls into this risk 
category157. Lp(a) has also been determined to be a causal and independent risk factor for other 
CVDs such as peripheral vascular disease, ischemic stroke, and calcific aortic valve 
stenosis83,154,158–161. 
Despite substantial evidence implicating Lp(a) as an independent and casual risk factor for 
CVD, current research is still addressing a definitive resolution to the question underlying the 
“Lp(a) hypothesis”: that specifically lowering Lp(a) levels confers a protective effect with 
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respect to CVD risk. Findings from recent large-scale clinical trials of anti-PCSK9 antibodies 
do suggest a benefit associated with Lp(a) reduction independent of other factors69,70, but 
conclusive evidence for such a phenomenon will likely remain beyond reach until therapies 
targeting Lp(a) specifically, and effectively, can be assessed in large prospective studies. 
1.1.8 Lipoprotein(a)-lowering therapies 
Since its discovery in 1963, a number of therapies have been shown to reduce Lp(a) levels but 
until recent years there have been few options that are effective beyond modest reduction – 
and fewer still that are specific for Lp(a). The most well-established class of lipoprotein-
lowering drug, the statin, while highly effective at reducing plasma levels of LDL, exhibits a 
complete lack of efficacy in reducing Lp(a)162,163, with some trials even reporting increases in 
Lp(a) with statin treatment164. These reports call our understanding of the mechanism of Lp(a) 
catabolism through the LDLR into question73,74. The therapeutic options that are known to 
lower Lp(a) fall into four broad categories: antibodies, nucleic acids, small molecules, and non-
pharmacological interventions. A summary of drug class, specificity, mechanism of action, 
and availability can be found in Table 1.1. 
1.1.8.1 Antibodies that lower Lp(a) concentration 
There are two targets to which FDA-approved antibody therapy is available with secondary 
effects on Lp(a) lowering: PCSK9 and the IL-6 receptor. While they are not specific for Lp(a), 
monoclonal antibody inhibitors of PCSK9 (evolocumab, alirocumab) and the IL-6 receptor 
(tocilizumab) have been shown to reduce plasma Lp(a) levels by up to 30% and 40%, 
respectively69,165–167.  
Mechanistically, the interaction of PCSK9 with the LDLR prevents LDLR recycling to the 
plasma membrane and instead promotes its intracellular degradation168. Antibody inhibition of 
PCSK9 by evolocumab or alirocumab prevents the interaction between PCSK9 and the LDLR, 
thereby increasing the plasma membrane abundance of the LDLR and enhancing clearance of 
apoB-100-containing lipoproteins (primarily LDL) from the plasma169,170. The finding that 
anti-PCSK9 antibody therapy is able to reduce Lp(a) levels by up to 30% suggests that there 
may indeed be a role for the LDLR in Lp(a) internalization under the right circumstances: when 
circulating LDL is low171. On the other hand, there is also evidence of decreased Lp(a) 
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production in response to antibody blockage of PCSK9171,172, suggesting the mechanism of 
Lp(a) lowering by this approach is complex. 
In the case of the IL-6 receptor, Lp(a) reductions of up to 41% have been reported in patients 
undergoing treatment for rheumatoid arthritis with the IL-6 receptor antibody 
tocilizumab166,167. It is theorized that the blockade of IL-6 signaling prevents the induction of 
LPA expression under control of the IL-6 response element mentioned in Section 1.1.3. 
1.1.8.2 Nucleic acid-based therapies for Lp(a) lowering 
Perhaps most promising in the context of Lp(a) lowering therapy are the recent reports of 
nucleic acid-based therapies targeted specifically to reduce translation of apo(a). Both 
antisense oligonucleotide (ASO) and double-stranded RNA-interfering (RNAi) options are 
currently in development and reduce Lp(a) specifically, rather than reducing Lp(a) as a 
secondary effect of apoB-100-targeted approaches. The ASO IONIS-Apo(a)-LRx binds 
specifically to LPA mRNA and targets it for degradation by RNase H1, with a documented 
downstream Lp(a) reduction of up to 92%173. AMG890 is an RNAi option in development by 
Amgen, specifically targeting LPA mRNA as well. While little is known about this brand new 
drug, Lp(a) reductions of 85-90% in non-human primates have been reported174. 
Nucleic acids that are not specific to Lp(a) but still reduce plasma Lp(a) levels include 
mipomersen65,66 (ASO targeted against APOB mRNA)  and inclisiran175,176 (RNAi against 
PCSK9 mRNA). Mipomersen and inclisiran have been reported to reduce circulating Lp(a) by 
up to 39% and 25%, respectively65,66,175,176. 
1.1.8.3 Small molecule approaches to Lp(a) lowering 
To date, no small molecules exist to specifically lower plasma Lp(a). A number of small 
molecules (on the market, and discontinued) have been shown to reduce Lp(a) as a secondary 
effect. These include niacin177, lomitapide (microsomal triglyceride transport protein 
inhibitor)67, and cholesteryl ester transport protein inhibitors such as anacetrapib178,179. At 
present, niacin is the only pharmacological intervention recommended for lowering Lp(a) by 
both the European Atherosclerosis Society157 and the National Lipid Association180. Decreases 
in plasma Lp(a) concentrations as high as 40% have been reported with niacin therapy181, but 
multiple large-scale trials have failed to find reductions in major cardiovascular events despite 
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the positive impact of niacin on plasma lipid profiles181–183. The limited set of small molecules 
with Lp(a)-reducing effects produce modest effects at best, leaving an open market for orally-
active Lp(a)-specific therapeutics. 
1.1.8.4 Lipoprotein apheresis 
Lipoprotein apheresis (LA) is not dissimilar in principle to hemodialysis: whole blood or 
plasma is circulated extracorporeally through resins, matrices, or filters designed to extract 
specific lipoproteins, before it is returned to the vasculature. LA most commonly extracts 
apoB-100-containing lipoproteins including both LDL and Lp(a). LA is an important therapy 
in those patients with homozygous familial hypercholesterolemia (HoFH), offering a sustained 
reduction in Lp(a) of 25-40%184, and reducing 5-year risk of major adverse coronary events by 
up to 86% in long-term studies185–187. This decreased risk is due to the simultaneous reduction 
of LDL and Lp(a) in these studies. As such, it is not possible to properly quantify the relative 
contribution of lowering Lp(a) to overall risk reduction. 
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Table 1.1. Therapies that have been shown to reduce plasma Lp(a) concentrations. 
Agent Class % Lp(a)  
Lp(a)-
specificity? 
Mechanism of action 
Alirocumab 
Monoclonal 
antibody 
30 No 
Inhibition of PCSK9; ↑ LDL 
receptor no.; ↓ apo(a) 
secretion 
E06 † 
Monoclonal 
antibody 
N/A No 
Blockade of pro-
inflammatory oxPL on Lp(a) 
Evolocumab 
Monoclonal 
antibody 
30 No 
Inhibition of PCSK9; ↑ LDL 
receptor no.; ↓ apo(a) 
secretion 
Tocilizumab 
Monoclonal 
antibody 
30 No 
IL-6 receptor blockade; ↓ 
transcription of LPA mRNA 
AMG 890 † RNAi 85-90▵ Yes ↓ translation of LPA mRNA 
Inclisiran † RNAi 14-25 No 
↓ translation of PCSK9 
mRNA 
IONIS-Apo(a)Rx 
✶ 
ASO 70 Yes ↓ LPA mRNA 
IONIS- 
Apo(a)-LRx † 
ASO 90 Yes 
↓ LPA mRNA; targeted to 
hepatocytes by conjugated 
GalNAc modification 
Mipomersen ASO 21-39 No ↓ APOB mRNA 
Anacetrapib ✶ Small molecule 36 No 
Unknown (secretion of 
apoB?) 
Lomitapide Small molecule 15-20 No 
MTP inhibitor; ↓ secretion of 
apoB-containing lipoproteins 
Niacin Small molecule 25 No 
↓ cAMP-mediated 
transcription of LPA 
Lipoprotein 
apheresis 
N/A 
70 (acute) 
25-40 
(sustained) 
No 
ApoB- or apo(a) affinity-
based extracorporeal removal 
of lipoproteins from plasma 
 
 † Therapy in development 
✶Development halted 
 ▵ Demonstrated in non-human primates 
Adapted with modifications from Borrelli et al. (2019)188. 
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1.2 Aims, rationale, & hypotheses 
It has been shown that there is a clear and substantial role for the KIV10 sLBS of apo(a) in 
thrombosis and fibrinolysis, and in the modulation of inflammatory gene expression in vascular 
cell types5,110,141. However, the direct contributions of the KIV10 covalent oxPL to the observed 
functions of apo(a)/Lp(a) are less clear, due in part to the difficulty associated with 
manipulation of a modification that we know relatively little about. Here, we seek to elucidate 
structure-function relationships attributable to the KIV10 domain of apo(a), in the context of 
both the sLBS and the covalent oxPL modification, as well as the structural requirement of 
sLBS function for oxPL addition. The aims of our work are targeted toward 1) expanding our 
understanding of the specific functions of the covalent oxPL addition to KIV10 in vitro, and 2) 
characterizing the lysine binding and oxPL status of recombinant apo(a) variants bearing 
nonsynonymous human-derived polymorphisms in the KIV10 sequence. We hypothesize that 
amino acid substitutions in the KIV10 domain of apo(a) will influence the functional 
characteristics of this kringle, by modulating its ability to bind lysine and/or host a covalent 
oxPL modification. Additionally, we hypothesize that the KIV10 sLBS and covalent oxPL are 
both relevant in the ability of apo(a) to induce inflammatory phenotypes in vascular cells, as 
reported previously14,189. 
1.2.1 Aim 1: generation of 17K apo(a) containing the KIV10 
His33→Ala substitution 
Identifying the precise amino acid residue in apo(a) that contains the covalent oxPL 
modification was an aim of a previous student from our group, following the determination 
that the oxPL is covalently bound within the KIV10 domain13, rather than within the KV domain 
as previously reported136. In order to identify the residue in question, a site-directed 
mutagenesis approach was used to substitute candidate residues in the KIV10 domain to alanine, 
generate recombinant KIV10KV proteins containing these mutations, and then assess the sLBS 
status (Section 2.7) and oxPL status (Section 2.8) of these proteins following purification. 
Candidate residues were determined based on the type of addition reaction required for 
covalent oxPL modification. Residues that could participate in a Michael addition reaction 
(His; Cys residues ruled out due to characteristic saturated disulfide bonding in kringle 
domains) or form a Schiff base (Arg, Lys) were each mutated individually using this approach. 
Following generation of these protein species and subsequent assessment of their sLBS and 
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oxPL status, it was determined that KIV10 His33 is likely the residue containing the covalent 
oxPL190. Of note, KIV10 His33→Ala was the only variant that retained its lysine binding 
ability, but lost reactivity with the E06 anti-oxPL antibody. Based on this information, the first 
aim was to generate and purify a variant of apo(a) with KIV10 His33→Ala in the context of 17 
KIV domains (17K H33A; corresponds to a naturally occurring apo(a) isoform size). Our goal 
was to use RNA-Seq to compare the transcriptome of differentiated THP-1 macrophage-like 
cells treated with 17K H33A to that of cells treated with the wildtype version of recombinant 
apo(a) (17K). We hypothesized that 17K H33A would induce only sLBS-dependent changes 
in gene expression, while 17K would induce both sLBS- and oxPL-dependent changes. Using 
this information, we sought to determine which effects of apo(a) treatment of these cells are 
due to the covalent oxPL exclusively, furthering our understanding of the potential 
contributions of Lp(a)/apo(a) to the progression of atherosclerosis. 
1.2.2 Aim 2: characterize the KIV10 mutations Met64→Thr and 
Arg10→Gln 
In a large-scale screening study performed by our Dutch collaborator Dr. Erik Stroes 
(University of Amsterdam), two patients were determined to possess unexpectedly low oxPL 
despite high Lp(a) levels. Blood samples from these patients were sent to our group, and the 
KIV10-encoding regions of their LPA alleles were sequenced. Each patient was heterozygous 
for a non-synonymous base substitution; one patient had an LPA variant encoding Thr at 
position 64 rather than Met (M64T), and the other, a Gln at position 10 rather than Arg (R10Q). 
In an effort to understand the contributions of these variants to the properties of KIV10, we 
sought to generate recombinant apo(a) variants containing M64T and R10Q substitutions and 
determine their lysine binding and oxPL status. We hypothesized that these substitutions 
would, in some way, influence the ability of KIV10 to bind lysine and/or be modified with a 
covalently-bound oxPL. 
 
 
 
 
30 
 
2 Materials and Methods 
2.1 Cell culture 
All cells were cultured in humidified atmosphere with 5% CO2 and 95% humidity, at 37 C.  
Human embryonic kidney 293 (HEK293) cells as described by Russel et al.191 were cultured 
in Minimum Essential Medium (MEM; Gibco) supplemented with 5% (v/v) fetal bovine serum 
(FBS; VWR International) and 1% (v/v) antibiotic/antimycotic (anti-anti; Gibco). HEK293 
cells were passaged at a ratio of 1:5 upon reaching 80% confluence.  
Human hepatocellular carcinoma (HepG2) cells were purchaced from American Type Culture 
Collection (ATCC; HB-8065™) cultured in Dulbecco’s Modified Eagle Medium Nutrient 
Mixture F-12 (DMEM/F12; Gibco), supplemented with 10% (v/v) FBS and 1% (v/v) anti-anti. 
HepG2 cells were passaged at a ratio of 1:5 upon reaching 80% confluence. 
Human THP-1 acute monocytic leukemia cells (THP-1 monocytes) were purchased from 
ATCC (TIB-202™) and cultured in Roswell Park Memorial Institute 1640 medium (RPMI-
1640; Gibco) supplemented with 10% (v/v) FBS, 1% (v/v) anti-anti, and 55 M -
mercaptoethanol (complete medium). THP-1 cells were cultured to maintain a density between 
3x105 and 1x106 cells/mL. 
2.2 Generation of apo(a) expression plasmids 
Wildtype apo(a) expression plasmids encoding 17-kringle IV (17K), 14-kringle IV (14K), 6-
kringle IV (6K), and a construct containing KIV10, KV, and the protease-like domain (10-P) in 
the pRK5 plasmid, and a wildtype apo(a) expression construct encoding only the KIV10 and 
KV domains of apo(a) (KIV10KV) in the pcDNA.4c plasmid, were all generated prior to this 
thesis13,14,190,192. Schematic diagrams of these apo(a) species can be found in Figure 2.1. All 
mutagenesis reactions were prepared according to manufacturers’ protocols and carried out in 
a BioRad T100 thermocycler. Sequences of primer pairs used can be found in Table 2.1. 
Mutations were verified via Sanger sequencing performed at the London Regional Genomics 
Centre (Robarts Research Institute, London, Ontario, Canada) using primer pair A/B for pRK5 
plasmids, and an in-house T7 promoter primer for pcDNA.4c plasmids. 
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Figure 2.1. Schematic representations of recombinant apo(a) species. 
Two full-length apo(a) variants were utilized in this thesis, along with three truncated variants. 
The full-length variants, 17K and 14K, contain one copy of each of the KIV domains, with the 
exception of KIV2, which is found in 8 and 5 copies, respectively. Additionally, these variants 
contain one copy of the KV and protease-like domains. The 6K apo(a) variant contains a fusion 
kringle of KIV1 and KIV5, along with one copy of each of KIV6 through KIV10, and one copy 
of the KV and protease-like domains. The 10-P variant contains only the KIV10, KV, and 
protease-like domains, while KIV10KV contains only the KIV10 and KV domains. Critically, 
all variants utilized in this thesis contain the KIV10 domain. 
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Table 2.1. Primer pairs used for KIV10 sequencing and mutagenesis reactions. 
Primer 
pair 
Forward (5’→3’) Reverse (5’→3’) 
A/B CCTAGAGACTCCCACTGTTGT CCCAGTAACAGTGGTTGCCTT 
C/D CATGACACCACACCGGgcgCAGAGGACCCCAG CTGGGGTCCTCTGcgcCCGGTGTGGTGTCAG 
E/F GGCCAGAGTTATCaAGGCACATTCTC GAGAATGTGCCTtGATAACTCTGGCC 
G/H GGCCAGAGTTATgcAGGCACATTCTC GAGAATGTGCCTgcATAACTCTGGCC 
I/J GTTTTACCAcGGACCCCAGCATC GATGCTGGGGTCCgTGGTAAAAC 
K/L CAGAGTTATCaAGGCACATTCTC GCCATTACCATGGTAGCA 
M/N ACCACACCGGaATCAGAGGAC GTCATGGATGACCAAGATTGAC 
O/P ACCACACCGGgcTCAGAGGACC GTCATGGATGACCAAGATTG 
Q/R CACACCGGCAaCAGAGGACCC GTGTCATGGATGACCAAGATTGAC 
S/T ACCACACCGGtATCAGAGGAC GTCATGGATGACCAAGATTGAC 
U/V TGTTTTACCAcGGACCCCAGC CCAAGGGCCTGTATCGGC 
*Bold-faced, lower-case letters indicate mismatched bases required for mutagenesis. 
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2.2.1 17K H33A 
A 17K plasmid containing the KIV10 His33→Ala substitution (pRK5.17K.H33A) was 
generated by site-directed mutagenesis using the QuikChange II XL Site-Directed Mutagenesis 
Kit (Agilent Technologies Inc.) with primer pair C/D under the following conditions: initial 
denaturation at 95 C (1 min), followed by denaturation at 95 C (50 sec), annealing at 60 C 
(50 sec), and extension at 68 C (11 min, 36 sec) for a total of 18 cycles, followed by a final 
elongation at 68 C (7 min). 
2.2.2 14K mutants 
14K plasmids containing the KIV10 substitutions Arg10→Gln (pRK5.14K.R10Q), 
Arg10→Ala (pRK5.14K.R10A), and Met64→Thr (pRK5.14K.M64T) were generated using 
the QuikChange II XL Site-Directed Mutagenesis Kit with primer pairs E/F, G/H, and I/J, 
respectively, under the same conditions indicated in Section 2.2.1 with the exception of 
extension for 10 min, 36 sec rather than 11 min, 36 sec. All three reactions were conducted 
with annealing at 60 C. 
2.2.3 6K mutants 
6K plasmids containing the KIV10 substitutions Arg10→Gln (pRK5.6K.R10Q) and 
His33→Asn (pRK5.6K.H33N) were generated using the Q5 Site-Directed Mutagenesis Kit 
with primer pairs K/L and M/N, respectively, under the following conditions: initial 
denaturation at 98 C (30 sec), followed by denaturation at 98 C (10 sec), annealing at 62 C 
and 67 C (30 sec), respectively, and extension at 72 C (4 min) for a total of 25 cycles, 
followed by a final elongation at 72 C (2 min). 
2.2.4 10-P mutants 
10-P plasmids containing the KIV10 substitutions His33→Ala (pRK5.10-P.H33A), 
His33→Asn (pRK5.10-P.H33N), His33→Gln (pRK5.10-P.H33Q), His33→Tyr (pRK5.10-
P.H33Y), and Arg10→Gln (pcDNA.4c.KIV10KV.R10Q) were generated using the Q5 Site-
Directed Mutagenesis Kit with primer pairs O/P, M/N, Q/R, S/T, K/L, respectively, under the 
following conditions: initial denaturation at 98 C (30 sec), followed by denaturation at 98 C 
(10 sec), annealing at 69 C, 67 C, 69 C, 67 C, and 62 C (30 sec), respectively, and 
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extension at 72 C (3 min) for a total of 25 cycles, followed by a final elongation at 72 C (2 
min). 
2.2.5 KIV10KV mutants 
KIV10KV plasmids containing the KIV10 substitutions Arg10→Gln 
(pcDNA.4c.KIV10KV.R10Q) and Met64→Thr (pcDNA.4c.KIV10KV.M64T) were generated 
using the Q5 Site-Directed Mutagenesis Kit with primer pairs K/L and U/V, respectively, under 
the following conditions: initial denaturation at 98 C (30 sec), followed by denaturation at 98 
C (10 sec), annealing at 62 C and 69 C (30 sec), respectively, and extension at 72 C (3 
min) for a total of 25 cycles, followed by a final elongation at 72 C (2 min). 
2.3 Generation of stably-expressing cell lines 
2.3.1 17K H33A 
HEK293 cells were co-transfected with the pRK5.17K.H33A and pRSVNeo plasmids (10 g 
and 0.5 g/100 mm culture dish, respectively) using MegaTran 1.0 transfection reagent 
(Origene) according to the manufacturer’s protocol. After 24 hours, transfected cells were 
exposed to 0.8 mg/mL Geneticin® selection antibiotic (ThermoFisher Scientific) until a viable 
population of cells was observed. Cells were then trypsinized, counted, and diluted to 8 
cells/mL in MEM, and 100 L of this cell suspension was then plated in each well of a 96-well 
plate. Once clonal populations of cells were observed, conditioned medium (CM) from each 
clone was assessed for the presence of apo(a) using an enzyme-linked immunosorbent assay 
(ELISA). An apo(a)-positive clonal population was selected for use after assessing expression 
and protein size by immunoblot of CM. ELISA reactivity and immunoblot signal obtained 
from CM from these clones was exceptionally weak in comparison to control CM from 
established lines. This process of stable line generation was repeated multiple times for 17K 
H33A, but apo(a) was only ever detectable in extremely small amounts. 
2.3.2 KIV10KV R10Q and KIV10KV M64T 
Separate populations of HEK293 cells were transfected with pcDNA.4c.KIV10KV.R10Q and 
pcDNA.4c.KIV10KV.M64T plasmids (10 g/100 mm culture dish) using MegaTran 1.0 
transfection reagent according to the manufacturer’s protocol. After 24 hours, cells were 
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exposed to 250 g/mL Zeocin™ selection antibiotic (ThermoFisher Scientific) until viable 
populations of cells were observed. 
2.4 Preparation of conditioned medium and cell lysates 
from stable- and transiently-transfected cells 
2.4.1 Stably-expressing cell lines 
HEK293 cells stably expressing proteins of interest were seeded with 5x105 cells/well in each 
well of a 6-well plate. Once the cells had formed a confluent monolayer, growth medium was 
removed and replaced with 750 L of serum-free Opti-MEM™ medium (Gibco). Serum-free 
medium was used in order to prevent serum proteins from interfering with immunoblot 
analysis. After 48 hours of incubation, CM was collected, supplemented with 1% (v/v) Protease 
Inhibitor Cocktail (PIC; Sigma), and frozen at -20 C until use. Cells were then lysed by the 
addition of 300 L V4 lysis buffer (50 mM Tris-HCl pH 7.4, 1% (v/v) NP-40, 0.25% (w/v) 
sodium deoxycholate, 150 mM NaCl, 1 mM EDTA). Whole cell lysates were collected and 
supplemented with 1% (v/v) PIC, homogenized by repeated shearing with a 20g needle, 
sonicated for 10 minutes at 40 kHz, and centrifuged at 21,000 x g for 10 minutes to pellet 
debris. Supernatants were collected and frozen at -20 C until use. Total protein concentrations 
of lysate samples were determined by bicinchoninic acid (BCA; Pierce™, ThermoFisher) 
assay prior to freezing. 
2.4.2 Transiently transfected cells 
Wildtype cells (HEK293 or HepG2) were seeded with 5x105 cells/well, in a 6-well plate. At 
approximately 65% confluency, cells were transfected using MegaTran 1.0 transfection 
reagent (Origene) according to the manufacturer’s protocol, using 2 g DNA/well. Cells were 
incubated with the transfection mixture for 24 hours, after which the transfection mixture was 
removed, cells were washed once with sterile 1X phosphate-buffered saline (PBS), and 750 
L of serum-free Opti-MEM™ was added. Collection of CM and whole cell lysates was then 
performed after 48 hours as described in Section 2.4.1. 
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2.5 Purification of recombinant apo(a) 
Recombinant apo(a) was purified from the CM of stably-expressing cell lines. Opti-MEM™ 
was used for this purpose, and was collected/replaced every 48 hours. After CM was collected, 
it was supplemented with 1 mM phenylmethylsulfonyl fluoride (PMSF), and stored at -20 C 
until purification. Prior to purification, CM was thawed, modified if necessary (i.e. for Ni2+ 
Sepharose® purifications), and passed through a 0.2 m asymmetric polyethersulfone (aPES) 
vacuum filtration system. 
2.5.1 Purification of recombinant 17K apo(a) species 
As previously described14, filtered CM was passed over a column containing Lysine 
Sepharose® 4B chromatography resin (GE Healthcare Life Sciences). The column was then 
washed extensively with wash buffer (0.5 M NaCl in 1X PBS), and then bound apo(a) was 
eluted with wash buffer supplemented with 200 mM -ACA. Eluted fractions were analyzed 
for light absorption at 280 nm (A280), and fractions with A280 > 0.100 were dialyzed extensively 
against 1X HEPES-buffered saline (HBS; 20 mM HEPES, 150 mM NaCl, pH 7.4), and 
concentrated using an Amicon® 10 kDa cutoff centrifugal filter unit (Millipore Sigma). 
2.5.2 Purification of recombinant KIV10KV apo(a) species 
Recombinant KIV10KV apo(a) species contained a His6 tag encoded by the pcDNA.4c 
plasmid, thereby allowing these proteins to be purified using Ni2+ Sepharose® chromatography 
resin. Prior to vacuum filtration, harvested CM was adjusted to 0.5 M NaCl and supplemented 
with 0.2 mM -metcaptoethanol, 5 mM imidazole, 2% (v/v) glycerol, pH 8.0. The modified 
CM was passed over a column containing Ni2+ Sepharose® excel chromatography resin (GE 
Healthcare Life Sciences). The column was washed extensively with KIV10KV wash buffer 
(50 mM NaH2PO4, 0.5 M NaCl, 1 mM -mercaptoethanol, 12 mM imidazole, pH 8.0), and 
then bound KIV10KV was eluted with KIV10KV wash buffer adjusted to 300 mM imidazole, 
pH 8.0. Eluted fractions were analyzed for A280, and fractions with A280 > 0.010 were dialyzed 
extensively against 1X HBS, and concentrated using an Amicon® 10 kDa cutoff centrifugal 
filter unit. 
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2.6 Purification of plasma-derived Lp(a) 
Lp(a) was purified with informed consent from the plasma of a fasted volunteer with high 
plasma Lp(a) levels and a single 16K apo(a) isoform as described previously26, with 
modifications. Up to 100 mL of whole blood was collected from the donor into EDTA-coated 
vacutainers® (BD Life Sciences). Plasma was isolated by centrifugation at 4 C and then 
supplemented with 100 M PMSF. Plasma density was adjusted to 1.02 g/mL with the addition 
of solid NaBr, the volume was adjusted to 40 mL with the addition of sterile 1X PBS, and the 
modified plasma was loaded into Quick-Seal centrifuge tubes (Beckman-Coulter) and heat-
sealed. Sealed tubes were centrifuged at 257,320 x g (50,000 rpm) using a Type 70 Ti rotor in 
a Beckman-Coulter Optima™ L-100 XP Ultracentrifuge for 18 hours at 10 C. The top layer 
of supernatant containing chylomicrons and VLDL was removed (these particles have a 
density of  < 1.02 g/mL), and the infranatant was collected. The infranatant density was then 
adjusted to 1.21 g/mL with the addition of solid NaBr, the volume was adjusted to 40 mL with 
the addition of 1X PBS, and the modified plasma was loaded into new Quick-Seal centrifuge 
tubes and heat-sealed. Sealed tubes were centrifuged as indicated in the previous step. After 
centrifugation, the top layer of the supernatant (the remaining lipoprotein fraction including 
Lp(a); these lipoproteins have a density of 1.02 g/mL <  < 1.21 g/mL) was extracted and 
dialyzed extensively against Buffer A (20 mM Tris-HCl containing 150 mM NaCl, 0.01% 
(w/v) NaN3, 0.01% (w/v) EDTA, pH 7.4). After dialysis, the lipoprotein fraction was diluted 
3-fold with 20 mM Tris-HCl, pH 7.4, and passed over a column containing DEAE-Sepharose® 
chromatography resin (GE Healthcare Life Sciences) that had been equilibrated with DEAE 
wash buffer (20 mM Tris-HCl, 50 mM NaCl, pH 7.4). The column was then washed 
extensively with DEAE wash buffer adjusted to 150 mM NaCl, 7.4, and Lp(a) was then eluted 
with DEAE wash buffer adjusted to 250 mM NaCl, pH 7.4. Eluted Lp(a) fractions were then 
pooled and dialyzed extensively against 1X HBS. Purified Lp(a) concentration was measured 
by BCA assay (Pierce, ThermoFisher Scientific), and purity was analyzed by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) followed by silver staining. Aliquots 
of the purified material were stored at -80 C. 
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2.7 Determination of lysine binding status of recombinant 
apo(a) using a lysine binding assay 
A chromatography column containing 1 mL of Lysine Sepharose® 4B chromatography resin 
was prepared. Next, 15 g of the purified protein of interest was diluted to 1.0 mL in wash 
buffer (Section 2.5.1) and passed over the column. The column was then washed five times 
with 1.0 mL of wash buffer to elute unbound material; these wash fractions were collected. 
Next, the column was subjected to a multi-step -ACA elution (100 nM, 1 M, 10 M, 100 
M, 1 mM, 10 mM, 100 mM, and 200 mM -ACA) in wash buffer. Elution fractions (12 
fractions of 1.0 mL each) were collected from this gradient elution. All fractions were assessed 
for the presence of apo(a) by immunoblot analysis using a polyclonal anti-apo(a) antibody 
(Affinity Biologicals, 1:10,000) following SDS-PAGE under reducing conditions. SDS-PAGE 
was conducted using a 12% polyacrylamide gel, and resolved proteins were transferred to a 
PVDF membrane in 1X transfer buffer (25 mM Tris-HCl containing 192 mM glycine and 10% 
(v/v) methanol). Proteins were defined as lysine binding-positive if they were eluted during 
the -ACA gradient elution, and lysine binding-negative if they were eluted during the wash 
steps. 
2.8 Determination of covalent oxPL modification of 
apo(a) by E06 immunoblotting 
KIV10KV apo(a) species (1 g) were resolved by SDS-PAGE using a 12% polyacrylamide gel, 
then transferred to a polyvinylidine difluoride (PVDF) membrane (Millipore Sigma) in 1X 
transfer buffer. The membrane was then blocked for 6 hours in E06 blotting buffer (20 mM 
Tris-HCl containing 150 mM NaCl, 1% (w/v) bovine serum albumin, 0.1% (w/v) NaN3, and 
0.27 mM EDTA, pH 7.4) at room temperature. The membrane was then incubated with E06 
primary antibody (Avanti Polar Lipids; 1:1000) for 12 hours at room temperature. Next, the 
membrane was washed with E06 blotting buffer before incubation with an anti-IgM HRP-
conjugated secondary antibody (Sigma; 1:7500) for 1 hour at room temperature, followed by 
another round of washing with E06 blotting buffer. Immediately prior to incubation with 
chemiluminescent substrate, the membrane was rinsed once with 1X Tris-buffered saline 
(TBS; 20 mM Tris-HCL containing 150 mM NaCl, pH 7.4). Immunoreactive bands were 
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visualized using SuperSignal West Femto Maximum Sensitivity Substrate (ThermoFisher 
Scientific) with a Bio-Rad ChemiDoc™ MP Imaging System. 
2.9 Detection of apo(a) by immunofluorescence 
microscopy 
2.9.1 Sample preparation 
HEK293 cells stably expressing 17K apo(a) or 17K H33A apo(a) were seeded at a density of 
2x105 cells/well in 6-well plates containing gelatin-coated 24 mm square glass coverslips. Cells 
were grown to approximately 65% confluency at which time they were fixed with 85% v/v 
ethanol, 5% (v/v) glacial acetic acid, and 10% (v/v) 37% formaldehyde for 1 minute and 
permeabilized for 5 minutes with 0.2% (v/v) Triton X-100 in 1X PBS. Following 
permeabilization, coverslips were blocked for 1 hour with immunofluorescence blocking 
buffer (5% (w/v) BSA and 0.1% (v/v) polysorbate 20 in 1X PBS). After blocking, coverslips 
were incubated in immunofluorescence blocking buffer containing 1-4 mouse primary 
monoclonal antibody against apo(a) (1:200) and a rabbit primary antibody against one 
intracellular marker of interest (calnexin, Abcam ab22595, 1:2000; trans-Golgi network 
integrated membrane protein 2 (TGN46), Abcam ab50595 1:100; early endosome antigen 1 
(EEA1), Abcam ab2900, 1:500; lysosomal-associated membrane protein-1 (LAMP-1),, 
Abcam ab24170, 1:100) for 1 hour at 37 C. Coverslips were then washed with 0.1% (v/v) 
polysorbate 20 in 1X PBS. Next, coverslips were incubated in immunofluorescence blocking 
buffer containing Alexa Fluor® 488-conjugated goat anti-mouse antibody and Alexa Fluor® 
568-conjugated goat anti-rabbit antibody (ThermoFisher Scientific; 1:125) for 30 minutes at 
37 C. Finally, coverslips were washed with 0.1% (v/v) polysorbate 20 in PBS, incubated with 
DAPI (1:3000) in 1X PBS for 5 minutes at room temperature, washed with 1X PBS, and then 
mounted on glass microscope slides using Shandon™ Immu-Mount™ (Fisher Scientific). 
2.9.2 Imaging of apo(a)-expressing cells 
For the purpose of qualitatively assessing the presence of apo(a) in stable cell lines, slides were 
imaged using a Zeiss Imager.Z2 microscope with AxioVision Rel. 4.8 software. Images were 
acquired using a 20 times magnification objective. 
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To determine intracellular localization of apo(a) in 17K and 17K H33A stable lines, slides 
were imaged using a Leica Sp8 scanning confocal microscope with Leica Application Suite X 
(LASX) software. Images were acquired at 2048 x 2048 resolution using a 63 times 
magnification objective with 1.518 refractive index immersion oil, as well as six times digital 
zoom. 
Co-localization of apo(a) with organelle markers was quantified using LASX, with background 
and threshold set at 10% and 70%, respectively, for both channels.  
2.10 Illumina MiSeq Next Generation Sequencing: 
characterizing the apo(a) transcriptome in human 
macrophage-like cells 
THP-1 monocytes were suspended at a density of 8x105 cells/mL in RPMI-1640 medium 
supplemented with 100 nM phorbol-12-myristrate-13-acetate (PMA) to induce protein kinase 
C-mediated differentiation to macrophages193. 24-well plates were seeded with 1 mL/well of 
this suspension. After 36 hours, cells were supplied with fresh PMA-supplemented medium. 
After a further 36 hours, this medium was replaced with serum-free complete medium (Section 
2.1) and incubated for 16 hours (starvation conditions); this was done in order to maximize 
sensitivity to treatments as previously described14. Following starvation, the medium was 
replaced with fresh serum-free medium supplemented with 250 nM Lp(a), 17K apo(a), 17K 
D56A apo(a), or no supplement. Each of the aforementioned treatments was performed in the 
absence of presence of 200 mM -ACA (to inhibit lysine binding) for a total of 8 treatment 
groups, performed in duplicate. This represented a single biological replicate for each 
treatment. Cells were incubated with the treatments for 6 hours, after which total RNA was 
isolated using the QIAGEN RNeasy Mini Kit according to the manufacturer’s protocol.  
RNA was submitted to the London Regional Genomics Centre (LRGC) for analysis using the 
Illumina NextSeq 500 (Illumina Inc.). Total RNA samples were quantified using the Qubit 2.0 
Fluorometer (ThermoFisher Scientific). Quality was assessed using the Agilent 2100 
Bioanalyzer (Agilent Technologies Inc.) and the RNA 6000 Nano kit (Caliper Life Sciences). 
Samples were then processed using the Vazyme VAHTS Total RNA-seq (H/M/R) Library 
Prep Kit for Illumina (Vazyme) which includes ribosomal RNA reduction. Samples were 
depleted and fragmented prior to cDNA synthesis, then cDNA was indexed, cleaned-up and 
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amplified via polymerase chain reaction. Biological replicate libraries were pooled into one 
library per treatment. The pooled library size distribution was assessed on an Agilent High 
Sensitivity DNA Bioanalyzer chip (Agilent Technologies Inc.), and quantified using the Qubit 
2.0 Fluorometer. The library was sequenced as a single end run, 1 x76 bp, using a High Output 
v2 kit (75 cycles). Fastq data files were downloaded from BaseSpace and analyzed using Partek 
Flow. After importation, data was aligned to hg19 using STAR 2.5.3a and annotated using 
RefSeq Transcripts 90. Features with more than 5 reads were normalized using counts per 
million (CPM), then -fold change and p-values were determined using Partek Flow’s Gene 
Specific Analysis (GSA). 
2.11 Statistical methods for data analysis 
Data are presented as mean ± standard error of the mean (SEM). Apo(a)-organelle co-
localization was determined using LASX, and analyzed using two-tailed students t-tests with 
significance set at p<0.05. Relative E06 reactivity of KIV10KV species was determined by 
densitometric analysis using BioRad Image Lab™ Software 6.0.1, and analyzed using a two-
tailed Welch’s t-test with significance set at p<0.05. Significance for next generation 
sequencing output was set at p<0.05 unless indicated otherwise, and determined using Partek 
Flow’s GSA. 
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3 Results 
3.1 The amino acid residues KIV10 His33 and KIV10 
Arg10 are required for processing and secretion of apo(a) 
Previous work has shown that the LPA gene contains several “null” alleles, wherein no apo(a) 
protein is detectable in the plasma that corresponds to the null. Null alleles for LPA have been 
shown to exist in both “transcript-negative” and “transcript-positive” forms in cultured baboon 
hepatocytes: transcript-negative null alleles are either not transcribed or generate a highly 
unstable transcript, and typical transcript-positive null alleles generate apo(a) species that are 
translated into the ER but are unable to be secreted, as defined by White et al.40. Additionally, 
a different variety of null allele leads to the secretion of apo(a) species that are unable to form 
Lp(a) due to truncations prior to the kringle domains required for Lp(a) assembly71,88. 
Unfortunately, the White et al. report40 of ER-retained apo(a) species preceded the wide 
availability of high-throughput DNA sequencing methods, and, as such, DNA sequences 
corresponding to the transcript-positive null apo(a) species described previously were not 
determined. At the time of publication, however, the authors speculated that DNA mutations 
may have given rise to “rogue” kringles that are unable to properly fold, and cause apo(a) 
species containing them to be retained in the ER. This is of key interest to the results presented 
herein, as we have demonstrated a molecular basis for ER-retained apo(a) species 
corresponding to the transcript-positive null allele expression phenotype described 
previously40. In our study, we have identified two key amino acid residues in apo(a) KIV10 that 
are absolutely required for the normal processing and secretion of apo(a): Arg10 and His33. 
3.1.1 17K H33A is translated, but not secreted by HEK293 cells 
Substitution of the His33 residue in KIV10 was originally conceived as a means of generating 
an apo(a) protein species that would retain KIV10 sLBS function, but would be incompatible 
for covalent oxPL addition. This proposal was based on previous findings from our group 
indicating that KIV10 His33 may serve as the site of oxPL modification190. As such, the first 
step was to generate and purify 17K H33A apo(a) to characterize the functional role of the 
covalent oxPL in KIV10. In order to achieve this, a plasmid encoding this apo(a) variant 
(pRK5.17K.H33A) was generated using site-directed mutagenesis. A line of HEK293 cells 
stably expressing 17K H33A was established using the method described in Section 2.3.1. CM 
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from this cell line was collected, but no apo(a) was detectable in this medium by immunoblot. 
This result was consistently reproduced over a number of attempts made to generate this stable 
line, prompting immunofluorescent staining to determine if the cells were able to produce the 
protein, but unable to secrete it, as described previously40 (Figure 3.1). After observing that 
apo(a) was abundant within the 17K H33A-expressing cells using immunofluorescence, but 
undetectable in CM from these cells, an immunoblot of CM and cell lysates was performed to 
compare the wildtype 17K cell line to the 17K H33A line (Figure 3.2). Two distinct sizes of 
apo(a) were present in the lysates of 17K-expressing cells, but only the larger size 
(corresponding to mature apo(a)) was detected in CM. In the lysates from the 17K H33A-
expressing cells, only the smaller size (corresponding to unprocessed/immature apo(a)) was 
detected, and no apo(a) was detected in the corresponding CM. 
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Figure 3.1. HEK293 17K H33A cells exhibit abundant apo(a) content. 
Wildtype, 17K, and 17K H33A (stably-expressing) HEK293 cells were prepared for imaging 
as described in Section 2.9, and were stained for apo(a) using the 1-4 mouse monoclonal 
primary antibody and Alexa Fluor® 488-conjugated anti-mouse secondary antibody (green), 
and nuclei using DAPI (blue). Cells were imaged at 20 times magnification in all cases using 
a Zeiss Imager.Z2 microscope with AxioVision Rel. 4.8 software. Scale bar = 50 m. 
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Figure 3.2. 17K H33A is not secreted, and is found at a reduced molecular weight in cell 
lysates. 
CM and whole cell lysates were collected from HEK293 cells stably expressing 17K and 17K 
H33A variants of apo(a). Lysate samples contained a total of 15 g protein as determined by 
BCA assay. Each CM sample was prepared using a volume of CM that was proportional to the 
volume of lysate used for the corresponding lysate sample, to approximately control for cell 
number. Samples were analyzed by SDS-PAGE using a 7% polyacrylamide gel under non-
reducing conditions, and resolved proteins were transferred to a PVDF membrane and 
immunoblotted for apo(a) using the mouse 1-4 monoclonal antibody. Band sizes 
corresponding to mature and immature forms of apo(a) are indicated. MW = molecular weight 
marker. 
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3.1.2 Truncated apo(a) species with additional KIV10 His33 
substitutions are translated, but not secreted by HEK293 cells 
After identifying that 17K H33A apo(a) was present within cells but not secreted, different 
apo(a) variants were explored, as well as different substitutions to replace His33. The goals of 
this process were to determine 1) if the apo(a) isoform used, in this case 17K, was a factor in 
the observed lack of secretion, and 2) if residues other than alanine, and more similar to 
histidine, would be less disruptive at position 33. Initially, plasmids encoding substitutions of 
H33N, H33Q, and H33Y (based on similarity to histidine, without the potential for oxPL 
addition) were generated by site-directed mutagenesis in the context of pRK5.10-P – a plasmid 
expressing a truncated variant of apo(a) that contains the critical KIV10 domain, as well as the 
KV and protease-like domains. Apo(a) was detectable in CM from cells transfected with the 
wildtype 10-P plasmid, but not the mutant variants (Figure 3.3). No apo(a) was detectable in 
the lysates of the transfected cells corresponding to either wildtype or mutant plasmids. In light 
of the low abundance of recombinant 10-P species, further experiments utilized the pRK5.6K 
plasmid, which exhibits very high expression levels of the corresponding recombinant protein 
and possesses the critical KIV10 domain. 
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Figure 3.3. 10-P apo(a) variants with substitutions to KIV10 His33 are not secreted.  
CM was collected from HEK293 cells transiently transfected with variants of the 10-P apo(a)-
encoding vector. All samples were prepared under non-reducing conditions, and an equal 
volume of CM was used to make up each sample. Samples were analyzed using SDS-PAGE 
with a 12% polyacrylamide gel, resolved proteins were transferred to a PVDF membrane, and 
immunoblotted for apo(a) using the mouse a34 monoclonal antibody. MW = molecular weight 
marker. 
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In the context of pRK5.6K, an H33N substitution was introduced to further test the effects of 
His33 substitution on apo(a) secretion using an apo(a) variant that exhibits a relatively high 
level of expression, and, as such, was expected to be detectable in both CM and cell lysates. In 
order to also address the possibility that previous observations of non-secretion were cell type-
specific, transient transfections of 6K and 6K H33N were performed in HepG2 cells in addition 
to HEK293, since human hepatocytes synthesize apo(a) in vivo. In this experiment, the 6K 
H33N apo(a) variant showed the same pattern of expression as 17K H33A: in both cell types, 
no apo(a) was detectable in CM, and only a smaller-sized, incompletely processed apo(a) 
species was detectable in lysates from cells transiently transfected with this plasmid (compared 
with both sizes present in cells transfected with wildtype 6K) (Figure 3.4). 
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Figure 3.4. 6K H33N apo(a) is not secreted by HEK293 or HepG2 cells. 
CM and whole cell lysates were collected from (A) HEK293 and (B) HepG2 cells transiently 
transfected with recombinant 6K apo(a). All samples were prepared under non-reducing 
conditions. Lysate samples contained a total of 15 g protein as determined by BCA assay. 
CM samples were prepared using volumes of CM that were proportional to the volume of 
lysate used for the corresponding lysate sample, to approximately control for cell number. 
Samples were analyzed by SDS-PAGE using 4-20% polyacrylamide gradient gels 
(ThermoFisher Scientific), transferred to a PVDF membrane, and immunoblotted for apo(a) 
using a sheep -Lp(a) polyclonal antibody (Affinity Biologicals). Band sizes corresponding to 
mature and immature forms of apo(a) are indicated. Asterisk = proposed homodimer of 6K, 
MW = molecular weight marker. 
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3.1.3 17K H33A is retained in the endoplasmic reticulum in HEK293 
cells 
Histidine is present at position 33 in all apo(a) and plasminogen kringle domains4, and amino 
acid substitution at this position has never been reported. As such, no mechanisms have been 
proposed for the intracellular retention we have observed for protein species containing 
substitutions at this position. In an attempt to explain these observations in the context of 
previous work showing ER-retained species of apo(a) with the same expression phenotype40, 
confocal immunofluorescence microscopy was performed to assess the co-localization of 
mutated and wildtype apo(a) with a number of subcellular structures: ER (calnexin), trans-
Golgi (TGN46), early endosomes (EEA1), and lysosomes (LAMP-1), as described in Section 
2.9. It was determined that 17K H33A exhibits higher co-localization with calnexin than does 
wildtype 17K (Figure 3.5). 
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Figure 3.5. 17K H33A apo(a) exhibits increased co-localization with calnexin compared 
with wildtype 17K. 
HEK293 cells stably expressing 17K apo(a) (17K) or 17K H33A apo(a) (17K H33A) were 
immunostained for apo(a) (green) and intracellular markers of interest (red). Apo(a) was co-
stained alongside (A) calnexin, ER; (B) TGN46, trans-Golgi (C) EEA1, early endosomes; (D) 
lysosomes, LAMP-1; representative images are shown. The 17K H33A apo(a) variant (n=3) 
exhibited greater co-localization with calnexin than the 17K wildtype (n=3) (p=0.01). Each 
biological replicate represents the set of values obtained from analysis of organelle co-
localization in 3 individual cells from a single experiment. Data are shown as mean  SEM 
(*p=0.01) determined by two-tailed students t-test. Cells were imaged at 63 times 
magnification with 1.518 refractive index oil and six times digital zoom, in all cases, using a 
Leica Sp8 scanning confocal microscope with Leica Application Suite X software. Scale bar 
= 10 m. 
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3.1.4 6K R10Q is translated, but not secreted by HEK293 and HepG2 
cells 
In collaboration with Dr. Erik Stroes (University of Amsterdam), the substitution of 
Arg10→Gln (R10Q) in apo(a) KIV10 was first proposed as a potential modulator of apo(a) 
function after it was observed that an individual with high Lp(a) levels, but unexpectedly low 
oxPL, was heterozygous for this substitution. In order to characterize any functional 
differences imparted to apo(a) by Gln at KIV10 position 10, we sought to generate recombinant 
apo(a) species bearing this change, and to subsequently assess lysine binding and oxPL status 
of these variants in comparison to wildtype apo(a). Initially, this substitution was generated in 
the context of pcDNA.4c.KIV10KV and pRK5.10-P, but no apo(a) was detectable in the CM 
or cell lysates from HEK293 cells transfected with these plasmids. As such, a pRK5.6K.R10Q 
plasmid was generated by site-directed mutagenesis with the goal of increasing overall 
abundance. A transient transfection experiment was conducted with pRK5.6K.R10Q in the 
same way as for the pRK5.6K.H33N plasmid, using both HepG2 and HEK293 cells. A similar 
pattern of expression was observed for the R10Q variant as we observed for the H33X variants: 
no apo(a) was detectable in CM, and only a smaller protein, corresponding to an incompletely 
processed apo(a) species, was observed in cell lysates (Figure 3.6). 
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Figure 3.6. 6K R10Q apo(a) is not secreted by HEK293 or HepG2 cells. 
 (A) CM and (B) whole cell lysates were collected from HEK293 and HepG2 cells transiently 
transfected with variants of 6K apo(a). All samples were prepared under non-reducing 
conditions. Lysate samples contained a total of 15 g protein as determined by BCA assay. 
CM samples were prepared using volumes of CM that were proportional to the volume of 
lysate used for the corresponding lysate sample, to approximately control for cell number. 
Samples were analyzed by SDS-PAGE using 4-20% polyacrylamide gradient gels 
(ThermoFisher Scientific), transferred to a PVDF membrane, and immunoblotted for apo(a) 
using a sheep -Lp(a) polyclonal antibody (Affinity Biologicals). Band sizes corresponding to 
mature and immature forms of apo(a) are indicated. Asterisk = proposed homodimer of 6K, 
MW = molecular weight marker. 
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3.1.5 14K R10Q and 14K R10A recombinant apo(a) variants are 
translated, but not secreted by HEK293 and HepG2 cells 
While the 6K apo(a) minigene generally mimics the characteristics of its full-length apo(a) 
counterpart, it has been reported previously that results from experiments using this apo(a) 
variant do not always yield the same results as full-length apo(a)192,194,195. It was therefore 
important in our studies to verify that the observed pattern of non-secretion with 6K R10Q was 
also observed using a full-length apo(a) species. To test this, the R10Q mutation was 
introduced in pRK5.14K, as 14K apo(a) is a full-length, physiologically relevant isoform with 
high expression levels in cultured cells owing to its relevantly low number of KIV domains. 
With respect to the R10Q substitution, it is imperative to consider that this is a naturally 
occurring mutation in the human population (rs776662773, prevalence 0.01-0.03%), meaning 
that the implications of our in vitro characterization of this substitution, and of the importance 
of Arg10 in general, are of direct relevance to the study of apo(a) in humans. A 14K R10A 
variant was also generated in order to determine whether the observed characteristics from the 
R10Q version were the result of the presence of Gln10. A transient transfection experiment 
was conducted in HEK293 and HepG2 cells using wildtype, R10Q, and R10A variants of 14K 
apo(a). CM and cell lysates were collected and immunoblotted for apo(a). The wildtype 14K 
apo(a) was observed in lysates at two distinct sizes. The larger size was the only species 
detectable in CM. It was observed that only the smaller size of the R10Q variant was present 
in cell lysates; this was also observed for the R10A variant. These findings were consistent in 
both HepG2 and HEK293 cells (Figure 3.7). 
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Figure 3.7. R10Q and R10A variants of 14K apo(a) are not secreted by HEK293 or 
HepG2 cells. 
CM and whole cell lysates were collected from (A) HEK293 and (B) HepG2 cells transiently 
transfected with variants of 14K apo(a). All samples were prepared under non-reducing 
conditions. Lysate samples contained a total of 15 g protein as determined by BCA assay. 
CM samples were prepared using volumes of CM that were proportional to the volume of 
lysate used for the corresponding lysate sample, to approximately control for cell number. 
Samples were analyzed by SDS-PAGE using split 7/15% polyacrylamide gels. Resolved 
proteins were transferred to a PVDF membrane, and immunoblotted for apo(a) using a sheep 
-Lp(a) polyclonal antibody (Affinity Biologicals). Band sizes corresponding to mature and 
immature forms of apo(a) are indicated. -actin was visualized by Imperial™ protein stain 
(ThermoFisher Scientific). MW = molecular weight marker. 
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3.2 Met/Thr at KIV10 position 64 modulates the degree of 
covalent oxPL modification, but not sLBS function 
As described in Section 1.2.2, a second patient was identified by our collaborator Dr. Erik 
Stroes (University of Amsterdam) as possessing unusually low oxPL levels despite high Lp(a); 
upon KIV10 exon sequencing of this patient, a non-synonymous Met64→Thr (M64T) 
substitution was identified. Interestingly, despite both patients being classified as possessing 
unusually low oxPL, the M64T patient had nearly 50-fold greater apo(a)-associated oxPL than 
the R10Q patient. Further, most apo(a) alleles contain threonine at position 64 (“major allele”), 
and methionine replaces it in only 25-35% of alleles (“minor allele”). The apo(a) sequence our 
group has used historically encodes the minor allele4, so while the Thr64 substitution was not 
particularly rare (as was R10Q), it presented an opportunity to probe these two common 
variants for potential differences in KIV10 functionality. The M64T substitution was generated 
by site-directed mutagenesis in pcDNA.4c.KIV10KV. A line of HEK293 cells stably 
expressing this variant was generated, and recombinant protein was purified from the CM of 
these cells as described in Section 2.5.2. First, the lysine binding ability of the apo(a) KIV10KV 
M64T variant was characterized using the lysine binding assay described in Section 2.7, 
comparing it to the Met64 positive control, and a non-lysine binding negative control which 
contains a KIV10 Asp56→Ala substitution (Figure 3.8). Here, we found that the M64T variant 
binds lysine in a manner comparable to the corresponding Met64 variant. 
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Figure 3.8. The KIV10KV M64T apo(a) variant binds Lysine Sepharose® in a comparable 
manner to the Met64 variant. 
Lysine binding assays were conducted for each variant (D56A, negative control; Met64, minor 
allele, positive control; M64T, major allele) as described in Section 2.7. The D56A variant did 
not bind to the resin, and was eluted non-specifically during the wash steps. The Met64 variant 
remained bound to the resin and was specifically eluted by the lysine analog -ACA. Similar 
to the Met64 variant, the M64T variant remained bound to the resin and was eluted with -
ACA. MW = molecular weight marker, FT = flow-through fraction. 
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After determining that the lysine binding function of the KIV10KV M64T variant was not 
different from the corresponding Met64 variant, the presence of covalently-bound oxPL was 
assessed by E06 immunoblot as described in Section 2.8. Initially, the M64T variant was 
compared to the oxPL-deficient D56A variant to qualitatively determine its oxPL status 
(Figure 3.9a). After confirming that the M64T variant was oxPL-positive, we compared it to 
the Met64 variant to assess relative amounts of oxPL modification (Figure 3.9b). The relative 
amount of covalent oxPL associated with the M64T variant compared to the Met64 variant 
was determined by immunoblot densitometry to be approximately 2.8-fold (Figure 3.10).  
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Figure 3.9. Representative immunoblots comparing E06 reactivity of apo(a) KIV10KV 
M64T to KIV10KV D56A and Met64 KIV10KV. 
Purified KIV10KV proteins (1 g) were analyzed by SDS-PAGE using a 12% polyacrylamide 
gel. Resolved proteins were transferred to a PVDF membrane and immunoblotted for oxPL 
using the E06 -oxPL IgM (Avanti Polar Lipids). (A) KIV10KV M64T and D56A variants 
were compared to qualitatively assess the presence of covalent oxPL in the M64T variant, 
using the D56A variant as a negative control. Membrane was stripped using 0.5 M NaOH and 
re-blotted for apo(a) using a sheep -Lp(a) polyclonal antibody (Affinity Biologicals). (B) The 
KIV10KV M64T variant was compared to the Met64 variant to quantitatively assess relative 
E06 reactivity, and an Imperial™ protein stain (ThermoFisher Scientific) was conducted to 
control for mass of loaded proteins. In both (A) and (B), sample reduction using 10 mM 
dithiothreitol (DTT) abrogated E06 signal. MW = molecular weight marker. 
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Figure 3.10. Relative oxPL signal abundance determined by E06 immunoblot 
densitometry of apo(a) KIV10KV Met64 and M64T variants. 
KIV10KV M64T exhibited a mean oxPL immunoblot signal intensity that is 2.8 (0.2)-fold 
greater than the Met64 variant (n=3). Each biological replicate represents the densitometric 
comparison of E06 signal for each protein variant after controlling for mass of loaded protein 
using the Met64 band as the reference point in each case. Data are shown as mean  SEM (*p 
= 0.01); analysis of significance was determined by two-tailed Welch’s t-test. 
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3.3 The structure and functions of apo(a) KIV10 are 
implicated in the induction of pro-atherogenic phenotypes 
in macrophage-like cells 
The covalent oxPL of apo(a) has previously been implicated by multiple sources as an 
important contributor to the induction of inflammatory phenotypes in vascular cells14,140,189. 
However, the exact contributions of the covalent oxPL to these inflammatory phenotypes have 
not been extensively characterized. At the outset of this project, we sought to directly assess 
gene induction effects attributable exclusively to the covalent oxPL by comparing the 
transcriptome of THP-1 macrophages treated with wildtype apo(a) (17K; sLBS- and oxPL-
positive) to that of cells treated with KIV10 His33-substituted apo(a) (17K H33A; sLBS-
positive, oxPL-negative). It was important to maintain the integrity of the KIV10 sLBS in this 
context since it has been shown that this functionality can contribute to the induction of pro-
inflammatory effects in vascular cell types110. Apo(a) species containing the covalent oxPL but 
lacking sLBS activity is not possible, as covalent oxPL addition cannot occur without lysine 
binding. After determining that substitution of KIV10 His33 results in a transcript-positive null 
allele for the LPA gene and, in turn, that purification and experimental use of this recombinant 
species would not be possible, our approach was modified to assess the effects of both the 
sLBS and the oxPL indirectly. We did this by utilizing the lysine analog -ACA to selectively 
eliminate lysine binding-dependent gene induction/repression in THP-1 macrophages treated 
with apo(a). To assess the effects that are solely attributable to the presence of the KIV10 oxPL, 
we compared the transcriptomes of THP-1 macrophages treated with 17K to those treated with 
a 17K version of the D56A variant (sLBS- and oxPL-negative), both in the presence of 200 
mM -ACA. We also compared the transcriptomes of THP-1 macrophages treated with 17K 
alone or 17K in the presence of 200 mM -ACA, to assess effects that are contingent on lysine 
binding, but represent the co-operative effects of apo(a) lysine binding and covalent oxPL 
(henceforth “LBS-facilitated effects”).  
Overall, these experiments included 8 treatments, as follows: 250 nM of either Lp(a), 17K 
apo(a), 17K D56A apo(a), or no treatment (NT) – each in the presence or absence of 200 mM 
-ACA (Figure 3.11). A t-distributed stochastic neighbour embedding (t-SNE) plot is shown 
to demonstrate the consistency we observed between biological replicates for each treatment 
(Figure 3.12). This variety of treatments yielded a very large data set and the opportunity to 
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make many comparisons, but only those comparisons which we felt were most relevant to the 
scope of this thesis were explored herein. 
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Figure 3.11. Experimental design of functional assay used to generate RNA for RNA-Seq 
analysis. 
(A) THP-1 monocytes were suspended at a density of 8x105 cells/mL in RPMI-1640 medium 
supplemented with 100 nM PMA. 24-well plates were seeded with 1 mL/well of this 
suspension. (B) After 36 hours, cells were supplied with fresh medium. (C) After a further 36 
hours, medium was replaced with serum-free medium and incubated for 16 hours (starvation 
conditions). (D) Following starvation, the medium was replaced with fresh serum-free medium 
supplemented with either 250 nM Lp(a), 17K apo(a), 17K D56A apo(a), or no supplement. 
Each of the aforementioned treatments was performed in the absence of presence of 200 mM 
-ACA (to inhibit lysine binding) for a total of 8 treatment groups, each performed in duplicate. 
Cells were incubated with the treatments for 6 hours. (E) Total RNA was isolated using the 
QIAGEN RNeasy Mini Kit according to the manufacturer’s protocol and sent to LRGC for 
RNA-Seq analysis. Figure created with Biorender.com. 
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Figure 3.12. t-SNE plot of biological replicates for RNA sequencing samples. 
t-distributed stochastic neighbour embedding converts a data set with many dimensions (i.e. 
expression for thousands of genes) to a data set with far fewer dimensions (in this case, three), 
while preserving the degree of similarity (or dissimilarity) between any given points. Each 
point in this t-SNE plot represents the gene expression attributable to a single biological 
replicate for the treatment corresponding to the colour of the point. The spatial clustering of 
biological replicates demonstrated in by t-SNE plot is indicative of high consistency within 
replicates for any given treatment, while the spatial separation of clusters is indicative of the 
differences in gene induction associated with each treatment. 
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3.3.1 The KIV10 covalent oxPL has functions in enabling immune 
function 
A number of genes were identified as being differentially regulated in THP-1 macrophages 
treated with 17K or 17K D56A apo(a), both in the presence of 200 mM -ACA. Since lysine 
binding-dependent interactions were inhibited in each of these treatments, it can be inferred 
that changes in gene expression were induced exclusively by the presence of the KIV10 
covalent oxPL in the 17K treatment. Genes with implications in the activity of the immune 
system, namely by recruitment of leukocytes and priming phagocytic cells to engulf apoptotic 
cells, were found to be differentially regulated owing to the presence or absence of the covalent 
oxPL (Table 3.1). A total of 127 genes were found to be differentially regulated in this 
comparison, with p < 0.05 and a -fold change of ≥ 2 or ≤ -2. 
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Table 3.1. Selected genes differentially expressed in THP-1 macrophages in response to the 
presence of the KIV10 covalent oxPL addition to apo(a). 
Gene 
-fold change  
(17K + -ACA vs. 17K D56A + -ACA) 
CCL18 +325.0 
GULP1 +5.9 
CHN2 +3.9 
LAX1 -320.3 
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3.3.2 The lysine-binding function of apo(a) facilitates the induction of 
inflammatory responses 
Next, we assessed the LBS-facilitated effects of apo(a) in gene induction. To do this, we 
compared the transcriptomes of THP-1 macrophages treated with either 17K apo(a) alone or 
17K apo(a) in the presence of 200 mM -ACA. This comparison allowed us to identify which 
genes were induced, or repressed, contingent on the lysine binding functionality of apo(a), 
representing the effects of both lysine binding and the covalent oxPL. Parameters for 
determining significance were set more stringently in this comparison, at p < 0.001 and a -fold 
change of ≥ 2 or ≤ -2. Many of the genes found to be differentially regulated have functions in 
immune activation and regulation; this finding was not explicitly represented in the top gene 
ontology (GO) terms that were found to be enriched in this comparison (Table 3.2), but the 
top Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways are highly indicative of 
inflammation (Table 3.3). Of the top 15 enriched KEGG pathways, 5 are directly related to 
the inflammatory processes of infection (bacterial, viral, or parasitic) and autoimmunity. A 
total of 1602 genes were found to be differentially regulated in this comparison. 
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Table 3.2. Top 15 enriched GO terms in THP-1 macrophages treated with 17K apo(a) 
compared to those treated with 17K apo(a) + 200 mM -ACA. 
GO term Enrichment score P-value 
DNA-binding transcription factor activity, RNA 
polymerase II-specific 20.06 1.93E-09 
DNA-binding transcription factor activity 19.01 5.53E-09 
tRNA modification 13.53 1.33E-06 
Transcription regulator activity 12.20 5.05E-06 
Regulation of transcription by RNA polymerase II 11.56 9.58E-06 
tRNA processing 11.16 1.42E-05 
Embryonic limb morphogenesis 11.06 1.58E-05 
Embryonic appendage morphogensis 11.06 1.58E-05 
Negative regulation of cell-cell adhesion 10.97 1.72E-05 
Regulation of signaling receptor activity 10.56 2.59E-05 
Negative regulation of cell population proliferation 10.20 3.73E-05 
Regulation of cellular process 9.71 6.10E-05 
Regulation of transcription, DNA-templated 9.69 6.19E-05 
Cytokine activity 9.69 6.22E-05 
Negative regulation of leukocyte cell-cell adhesion 9.59 6.86E-05 
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Table 3.3. Top 15 enriched KEGG pathways in THP-1 macrophages treated with 17K apo(a) 
compared to those treated with 17K apo(a) + 200 mM -ACA. 
KEGG pathway Enrichment score P-value 
Cytokine-cytokine receptor interaction 13.3 1.67E-06 
Neuroactive ligand-receptor interaction 8.37 2.31E-04 
Gap junction 6.81 1.10E-03 
JAK-STAT signaling pathway 6.77 1.14E-03 
Herpes simplex virus 1 infection 6.08 2.29E-03 
Salmonella infection 5.30 5.00E-03 
Legionellosis 4.86 7.79E-03 
MicroRNAs in cancer 4.79 8.29E-03 
Toll-like receptor signaling pathway 4.33 1.00E-02 
Transcriptional misregulation in cancer 4.25 1.00E-02 
Inflammatory bowel disease (IBD) 4.11 2.00E-02 
Lipoic acid metabolism 3.81 2.00E-02 
Homologous recombination 3.68 3.00E-02 
Folate biosynthesis 3.61 3.00E-02 
African trypanosomiasis 3.58 3.00E-02 
*Italicized pathways are directly related to infection (bacterial, viral, and parasitic), and 
autoimmunity. 
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3.3.3 Differential regulation of genes with atherogenic implications 
In addition to our assessment of GO terms and KEGG pathways, we examined the differential 
regulation of specific genes of interest in response to treatment with 17K apo(a) compared to 
17K apo(a) + 200 mM -ACA. We identified genes that were not differentially expressed in 
response to the addition of -ACA by excluding genes that showed differences when 
comparing the vehicle and vehicle + -ACA treatments (Figure 3.13a). Several roles are 
proposed for apo(a) in the development of atherosclerosis, rationalizing our investigation into 
the potential mechanisms underlying these effects. Thus, we considered genes from enriched 
GO terms and KEGG pathways, as well as previously established literature, to identify genes 
of interest with respect to the development of atherosclerosis. This subset included genes with 
roles in cell-cell adhesion, cell signaling, and modulation of the extracellular environment 
(Figure 3.13b). The differential regulation of this subset of genes is summarized in Figure 
3.13c. 
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Figure 3.13. Subset of genes which are differentially regulated by apo(a) dependent on 
the KIV10 sLBS and covalent oxPL, rationalized by a potential role in the pathology of 
inflammation and atherosclerosis. 
(A) Differences in gene expression were assessed in THP-1 macrophages treated with 17K 
apo(a) or 17K apo(a) + 200 mM -ACA, and also in THP-1 macrophages treated with vehicle 
or vehicle + 200 mM -ACA. Genes that were found to be differentially regulated in the 
presence or absence of -ACA were disqualified from further analysis, to prevent confounding. 
The differential regulation of these genes is deemed to be LBS-facilitated, encompassing both 
lysine binding- and oxPL-derived effects. (B) Genes appearing in GO terms and KEGG 
pathways enriched in the 17K vs. 17K + -ACA comparison were considered in the context of 
literature relating to atherosclerosis; genes with implications in inflammation were of greatest 
interest. Genes encoding proteins with potential implications in the pathology of 
atherosclerosis were selected. (C) Visual representation of differential gene regulation in THP-
1 macrophages treated with 17K apo(a) or 17K apo(a) + 200 mM -ACA, compared to vehicle. 
Inclusion of Lp(a) allows comparison to 17K apo(a) to visualize similarities and differences in 
gene regulation, thereby implying the importance of apo(a) in gene regulation by Lp(a). Heat 
map represents log2 (-fold expression) corresponding to the indicated treatment, compared to 
vehicle. 
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4 Discussion 
Elevated plasma Lp(a) concentration is now considered the single most prevalent heritable risk 
factor in the development of CVD196. Approximately 20% of the population is classified in a 
high- risk category, owing to plasma Lp(a) levels in excess of 50 mg/dL196; this classification 
alone predisposes this demographic to a >2-fold increased risk of myocardial infarction, when 
compared with the remaining 80% of the population154. Though an understanding of Lp(a) as 
a contributor to the development of CVD has been established by determining the risks 
associated with its elevation, our understanding of the specific mechanisms by which Lp(a) 
contributes to disease progression remains incomplete. Our imprecise understanding of the 
specific functionalities that underlie the robust pathogenicity of Lp(a) has no doubt given way 
to the bleak therapeutic landscape we are faced with today: there remains a complete lack of 
therapies available to specifically reduce Lp(a) levels, and further still, no approved therapies 
are available to specifically reduce its pathogenic potential. Indeed, the outlook for individuals 
with genetically elevated Lp(a) levels has been poor until recent years, which has brought an 
explosion of prospective Lp(a)-specific drugs into pre-clinical and clinical investigation188.  
A multifaceted approach to treating elevated Lp(a) levels – including specifically-targeted 
reduction of circulating particles – will be important moving forward. In light of this, however, 
exciting findings from a recent publication assessing oxPL blockade have provided important 
proof of principle to the notion that the pathogenicity of Lp(a) can be limited not only by 
reducing its abundance in the circulation, but also by masking key structural and/or functional 
components140. This study demonstrated that an anti-oxPL antibody fragment, E06-scFv, was 
able to reduce the severity and slow the progression of atherosclerosis in Ldlr-/- mice fed a 
high-cholesterol diet140. While this study did not make assessments with respect to Lp(a) 
specifically, the non-fragment version of the E06 antibody has been shown in numerous studies 
to bind to the covalent oxPL of Lp(a)/apo(a) in the same way as it binds to oxPLs found in 
oxLDL15,122,197. Further experiments using Lp(a) will be necessary to directly assess the effects 
of Lp(a)-oxPL blockade in this context, but a similar benefit is expected. Insights into the 
importance of oxPLs in CVD from both in vitro and in vivo studies continue to rationalize 
further investigation of structure-function relationships in Lp(a) and apo(a), especially those 
that may influence the presence, exposure, or abundance of the KIV10 covalent oxPL. 
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4.1 A molecular basis for novel transcript-positive apo(a) 
null alleles 
We have demonstrated that LPA alleles encoding substitutions for KIV10 Arg10 or His33 are 
able to be transcribed, but that the protein products of these transcripts are unable to be secreted 
by either HEK293 or HepG2 cells. These observations are consistent across different isoforms 
and truncated variants of apo(a) (e.g. 6K), indicating that we have indeed identified two amino 
acid residues that are absolutely necessary for the secretion of apo(a). Our findings match those 
of White et al. in baboon hepatocytes, who made identical observations of transcript-positive 
apo(a) species that were unable to be secreted40. A molecular basis for these ER-retained apo(a) 
species was not indicated by White et al., presumably due to limited access to DNA sequencing 
at the time of publication. At this time, White et al. postulated that spontaneous mutations may 
have led to the evolution of “rogue” kringles which are unable to fold properly and result in 
ER-retained apo(a) species. Our findings have both recapitulated these observations, and 
provided a molecular basis for them. Indeed, we have identified two independent non-
synonymous mutations in the KIV10-encoding region that are sufficient to generate a null 
expression phenotype for apo(a). 
Prior to our study, two null alleles were identified in the LPA gene. The first of which (SNP 
rs41272114) introduces a splice site mutation. This leads to an alternatively-spliced transcript 
whose protein product is truncated by a nonsense mutation in the KIV7 domain71. The other 
null allele (rs# unclear, “G4925A”89) generates a nonsense mutation within the repeating KIV2-
encoding sequence, specifically in the exonic donor splice site of the second KIV2 exon90. 
These null alleles share common characteristics: both truncated apo(a) variants are able to be 
secreted, neither can participate in the formation of Lp(a), and both are the result of nonsense 
mutations. In contrast, the novel null alleles we have identified lead to the translation of apo(a) 
species that are unable to be secreted, each the result of a unique nonsynonymous substitution. 
It is unclear whether these species are capable of covalent Lp(a) formation since they are not 
secreted, making Lp(a) assembly assays, as described previously64, impossible. While 
evidence of intracellular Lp(a) assembly has been demonstrated using the 6K apo(a) variant192, 
experiments using full-length apo(a) have not yielded the same result, suggesting that 
attempting similar experiments with KIV10 Arg10- and His33-substituted apo(a) species would 
be unreliable194,195. That being said, the inclusion of all kringles required for Lp(a) assembly 
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in these retained species suggests their hypothetical compatibility in the Lp(a) assembly 
process, further distinguishing them from previously reported LPA null alleles. 
4.2 Substitutions of apo(a) KIV10 Arg10: a double-edged 
sword? 
In terms of null alleles, KIV10 Arg10 may be considered even more interesting than His33 as 
a critical residue for apo(a) secretion given that it was originally rationalized for investigation 
after it was found to be substituted for glutamine (R10Q) in a human subject. As such, our 
finding that KIV10 Arg10-substituted apo(a) species are unable to be secreted can be assumed 
to hold true in humans, since this was the case in the context of 14K apo(a), which represents 
an isoform that naturally occurs in the population (unlike truncated constructs like 10-P or 6K). 
In collaboration with Dr. James Gauld (Windsor University), comprehensive in silico 
molecular modeling of the KIV10 R10Q domain is underway to more closely examine the 
structural changes that this substitution introduces in the KIV10 domain. This may, in the future, 
allow us to theorize about the possible mechanisms contributing to the intracellular retention 
of this variant that we have shown. In a purely speculative context, with the structure of KIV10 
in mind, Arg10 may act to coordinate the position of other amino acids during the folding of 
KIV10, a critical function that could explain why it is essential for the secretion of apo(a). 
Regardless of underlying mechanisms, the physiological implications for non-secreted apo(a) 
species such as the KIV10 R10Q variant are difficult to determine, largely owing to the fact 
that subjects bearing this particular substitution are too rare to allow studies in vivo. The SNP 
corresponding to the R10Q substitution (rs776662773) is found in 0.01-0.03% of LPA alleles, 
meaning that only one individual in every 2,500, on average, is a heterozygous carrier of this 
allele, and that one in 6.25 million individuals is homozygous. Until a cohort can be assembled 
that is large enough to sufficiently power a study of rs776662773 carriers, we are left little 
choice but to theorize about the implications associated with these types of null alleles. In this 
context, two key findings should be considered: 1) apo(a) species with the KIV10 R10Q 
substitution are translated, but not secreted, and as such are unable to participate in Lp(a) 
assembly, and 2) null alleles corresponding to apo(a) species which are unable to participate 
in Lp(a) assembly are associated with reduced Lp(a) levels and reduced risk of CVD71,88–90,198. 
While the mechanisms preventing these null apo(a) species from participating in Lp(a) 
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formation are markedly different, it is a hypothetical possibility that rs776667223 may be 
associated with reduced plasma Lp(a) concentrations and reduced CVD risk, similarly to other 
LPA null alleles.  
While cardiovascular health may stand to benefit in individuals expressing an R10Q-
substituted apo(a) variant, one must also consider the fate of the non-secreted apo(a) species. 
As we have shown in the HEK293 and HepG2 cell lines, transcript-positive null apo(a) species 
are retained intracellularly, and we have demonstrated that this retention occurs in the ER in 
HEK293 cells for KIV10 H33A-substituted apo(a). Further experiments are planned to 
determine if this is the case for KIV10 R10Q-substituted apo(a), and if this finding is 
recapitulated in HepG2 cells as well. A similar observation has been reported previously in a 
study of cultured primary baboon hepatocytes40, suggesting that this finding is likely to hold 
true across secretory cell types. Together, these findings suggest that R10Q-substituted apo(a) 
species may accumulate within the ER of hepatocytes in human rs776667223 carriers. 
Accumulation of misfolded proteins in the ER triggers their degradation via the ERAD 
pathway58–60, and chronic activity of the ERAD pathway gives way to the unfolded protein 
response (UPR)199,200. The UPR is characterized by global repression of protein synthesis and 
can eventually trigger apoptosis199. ER stress/UPR activation in hepatocytes has been 
characterized with respect to diseases of the liver such as non-alcoholic fatty liver disease 
(NAFLD)/non-alcoholic steatohepatitis (NASH), with our current understanding of the role of 
ER stress in NAFLD/NASH centered on dysregulation of lipid homeostasis in the liver201,202. 
Previous studies have demonstrated the ER stress-mediated activation of sterol regulatory 
element-binding proteins (SREBPs), transcription factors with roles in cholesterol metabolism, 
LDLR expression, and de novo lipogenesis203,204. For example, SREBP-1 plays an important 
role in fatty acid and triglyceride biosynthesis205. Additionally, one arm of the UPR increases 
nuclear localization of pro-apoptotic CHOP, a C/EBP-homologous protein206; this homology 
facilitates the interference of CHOP with C/EBP, a transcription factor whose normal 
function involves the regulation of gluconeogenesis and lipid homeostasis207. The combination 
of UPR-induced hepatocyte apoptosis with dysregulation of SREBP and C/EBP signaling, 
among other factors, seems to contribute to the ER stress-mediated disruption of hepatic lipid 
metabolism and sets the stage for fatty liver-related pathologies. Based on this understanding 
of the role of ER stress in fatty liver, it is reasonable to posit that without some means of gene 
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silencing, chronic ER retention of transcript-positive LPA null species may compromise the 
overall health of the liver in individuals who are carriers. Similar to the potential 
cardioprotective effect proposed above, this hypothesis is difficult to test since the population 
of KIV10 R10Q apo(a) variant carriers is very small. However, in vitro methods may shed light 
on the likelihood of increased NAFLD/NASH in such carriers; comparing the expression 
and/or activity of UPR markers such as CHOP, SREBP-1, or p-eIF2 in HepG2 cells stably 
expressing either wildtype or R10Q apo(a) may indicate if such an outcome is possible in 
human hepatocytes.  
4.3 Implications of the requirement of KIV10 His33 for 
apo(a) secretion 
In the context of this thesis, the substitution of His33 was rationalized as a means to investigate 
the identity of this residue as the site of covalent oxPL addition to apo(a), and to subsequently 
assess the functional contributions of the oxPL directly. In all kringles of apo(a) and in 
plasminogen K4, position 33 is indeed occupied by a histidine residue4; such an extreme degree 
of sequence conservation, coupled with our reported observations, suggests that this residue is 
truly indispensable for proper KIV kringle folding and/or function. It should, however, be 
noted that other kringles in plasminogen do contain substitutions at this position4. 
Unfortunately, this negates the idea of KIV10 His33 substitution as an in vitro tool for obtaining 
a more complete understanding of the structure-function relationships in KIV10 of apo(a), such 
as the mechanism of covalent oxPL addition. Future attempts to this end will require different 
approaches. Despite the highly conserved nature of His33, natural His33 substitution cannot 
yet be ruled out; reports of substitutions at this position may not exist simply because, until 
now, the relevance of such an observation has not been established, and we have not “looked” 
for it in humans. Additionally, the scarcity of rs776662773 (R10Q) suggests that transcript-
positive null alleles including those involving Arg10 or His33 substitution could be incredibly 
rare. However, for the time being, the obligate requirement for KIV10 His33 in the secretion of 
apo(a) is not applicable to humans beyond our in vitro findings in human-derived cell lines. 
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4.4 KIV10 Thr64 and the implications of enriched covalent 
oxPL modification 
We have shown, in the context of KIV10KV, that KIV10 Thr64 enriches covalent oxPL 
modification by nearly 3-fold in comparison with the same species that contains a methionine 
at this position. This finding is exciting in and of itself, as it is the first report of two apo(a) 
species that are both covalently modified with oxPL, but to differing extents. In addition to 
demonstrating this effect, we have provided a concrete molecular basis for it, solely attributable 
to the naturally occurring polymorphism resulting in a methionine/threonine substitution at 
KIV10 position 64. Additionally, there is potential significance in this finding as KIV10 Thr64 
and Met64 represent the major (~65%) and minor (~35%) alleles in the human population, 
respectively. This discrepancy in oxPL modification may represent a determinant of CVD risk 
that is currently not accounted for. The relationship between the M64T substitution and the 
increase in covalent oxPL modification we observe is currently unclear, but molecular 
modeling in collaboration with Dr. Murray Junop (University of Western Ontario) has shown 
subtle differences between the Met64 and Thr64 versions of KIV10, despite the overall shape 
of the domain remaining virtually identical (Figure 4.1). When comparing the Thr64 and 
Met64 versions of KIV10, the most obvious difference is that the Arg71 side chain is 
repositioned closer to His33, the residue where covalent oxPL addition has been proposed. 
Arg71 is one of seven amino acids required for KIV10 sLBS function, and as such we see that 
the orientation of the sLBS is changed slightly, rotating the modeled ligand’s carboxyl group. 
Currently, the mechanism by which the covalent oxPL is added to KIV10 is unknown. If His33 
is indeed the oxPL-modified residue, Thr64-mediated repositioning of Arg71 and reorientation 
of the lysine binding site may in turn change the electrochemical microenvironment of the 
His33 side chain in such a way that covalent oxPL modification is favoured more-so in the 
Thr64 variant than in the M64 variant. 
While we are only able to make educated guesses about the physiological implications of 
R10Q-substituted apo(a) species, the RNA-Seq-derived gene regulation data presented in 
Table 3.1 allow us to make more concrete hypotheses about the potential effects attributable 
directly to increased apo(a)-bound oxPL. We have shown that the oxPL alone induces strong 
up-regulation of the CCL18 gene which encodes CCL18 (aka pulmonary activation-regulated 
chemokine; PARC), a chemokine whose primary function is the recruitment of a wide variety 
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of immune cell types208–210. In addition to attracting immune cells, CCL18 exerts 
immunomodulatory effects in many of these cells, playing roles in both pro-inflammatory211 
and anti-inflammatory212 processes. Expression of CCL18 has been shown in human 
atherosclerotic plaques, and in situ RNA hybridization suggests that CCL18 expression is 
restricted to CD68+ macrophages213. What is very interesting in the context of our results is the 
expression pattern of CCL18 that has been demonstrated in vitro: while no differences in 
CCL18 expression were found in naïve THP-1 monocytes or PMA-differentiated THP-1 
macrophages incubated with oxLDL213, we have clearly shown that the covalent oxPL of 
apo(a) is capable of strongly inducing CCL18 expression under similar experimental 
conditions. In addition to inducing CCL18 expression, we have also shown that the covalent 
oxPL strongly represses the expression of LAX1, which encodes lymphocyte transmembrane 
adapter 1. This adapter protein is involved in the negative regulation of antigen-receptor 
signaling in both T- and B-cells214, implying that the covalent oxPL acts to facilitate a maximal 
inflammatory response in these cell types. This effect may synergize with that of CCL18, 
which potentially acts to recruit both T- and B-cells to the site of oxPL exposure. The sum of 
these effects would be to recruit various immune cell types to sites of atherosclerotic plaque 
development and enable a maximal inflammatory response, providing evidence for the role of 
the covalent oxPL in the initiation and propagation of atherosclerosis. These effects alone are 
enough to hypothesize that added oxPL enrichment of apo(a) may contribute to accelerated 
atherogenesis in vivo by increasing the potency of CCL18 induction and LAX1 repression. It is 
uncertain if these regulatory effects are threshold-based or if a proportional dose-response may 
be observed. In vitro comparisons of gene expression in macrophages exposed to Met64 and 
Thr64 variants of apo(a) may give further perspective with respect to the nature of these 
relationships. It is important to note that the Met64 variant of 17K apo(a) was used in the RNA-
Seq experiment we conducted, and that studies comparing Met64 and Thr64 variants of full-
length apo(a) represent a strong candidate for further investigation into the functional 
significance of the KIV10 covalent oxPL. 
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Figure 4.1. Molecular modeling overlay of Met64 (blue) and Thr64 (orange) variants of 
apo(a) KIV10, with -ACA as the bound ligand. 
The orientation of the peptide backbone is nearly identical between the Met64 and Thr64 
(M64T) variants of apo(a) KIV10, as shown. However, differences are apparent in the two 
variants: the orientation of the Arg71 (R71) side chain and the orientation of the carboxyl group 
of the bound ligand are altered. In comparison to the Met64 variant, the Thr64 variant Arg71 
side chain is closer to the side chain of His33 (H33). Arg71 is one of seven amino acids forming 
the sLBS of KIV10 (Arg71 being a component of the cationic center), and this repositioning in 
turn alters the orientation of the carboxyl group of the bound ligand. Additionally, if His33 is 
indeed the site of covalent oxPL addition as proposed190, the microenvironment of this residue 
as altered by the aforementioned differences may be more favourable for covalent oxPL 
addition in the Thr64 variant than in the Met64 variant, thereby explaining our observations. 
Figure created by Dr. M Junop and R Szabla using Rosetta Relax for energy minimization and 
PyMOL for structure visualization. 
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4.5 Apo(a) LBS-facilitated gene regulation effects have 
atherogenic implications 
Multiple in vitro studies have demonstrated potentially atherogenic KIV10 sLBS-dependent 
effects of apo(a) treatment in both endothelial cells110,141 and SMCs125,142. While endothelial 
cells and SMCs both have distinct roles in the development of atherosclerosis, cells of the 
immune system, such as macrophages, are critical in propagating the chronic inflammatory 
response that has been characterized within atherosclerotic plaques215,216. Thus, we sought to 
identify LBS-facilitated (lysine-binding and covalent oxPL-dependent) gene regulation effects 
of apo(a) in THP-1 macrophages in order to gain further understanding of the influence of 
apo(a) on cells involved in the inflammatory response. In this study, and in previous studies, 
the lack of an oxPL-negative/sLBS positive apo(a) species has prevented us from discerning 
effects that are attributable exclusively to the KIV10 oxPL versus those that rely on the physical 
interaction facilitated by the KIV10 sLBS. Indeed, we must consider that these lysine binding-
dependent effects, while requiring lysine binding, are not necessarily due to lysine binding. 
The close spatial proximity of the KIV10 sLBS and oxPL may facilitate the interaction of the 
covalent oxPL with ligands of the sLBS. In this context, while it has been demonstrated that 
the KIV10 sLBS has roles in thrombotic/fibrinolytic balance by way of physical interaction 
with fibrin and other substrates5,26,144,151, it is unclear whether these same types of physical 
interactions are capable of inducing signaling pathways in cells. We believe it is most 
reasonable to assume that apo(a)-mediated signaling that is contingent on lysine binding 
represents a co-operative process involving both the physical lysine binding process, as well 
as the exposure of bound ligands to the covalent oxPL. As such, we deem these effects to be 
“LBS-facilitated”. 
We utilized RNA sequencing to expand our understanding of structure-function relationships 
of the apo(a) KIV10 domain, and the data presented are focused on LBS-facilitated effects. 
While some downstream effects that require the lysine binding functionality of apo(a) have 
been characterized in other vascular cell types, this newer approach has provided us an 
opportunity to explore many potential mechanisms by which apo(a)/Lp(a) may contribute to 
atherosclerosis via modulation of the immune system. In order to acquire a broad 
understanding of these LBS-facilitated effects, we first considered the enriched GO terms and 
KEGG pathways associated with lysine binding-facilitated interactions of apo(a). Here, we 
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observed 5 entries directly related to infection (bacterial, viral, and parasitic) within the top 15 
enriched KEGG pathways, complimented by enrichment of the cytokine activity GO term and 
the cytokine-cytokine receptor interaction KEGG pathway. These GO terms and KEGG 
pathways share a common theme – signaling in inflammatory processes – which supplies 
evidence for the proposed pro-inflammatory roles for apo(a)/Lp(a) in facilitating the initiation 
and progression of atherosclerosis. In this study, we have demonstrated the enrichment of 
numerous inflammation-associated GO terms and KEGG pathways, as well as the differential 
regulation of individual genes with atherogenic implications. 
In addition to the enriched GO terms and KEGG pathways we have identified in Table 3.2 and 
Table 3.3, we assessed a subset of genes fitting the following criteria: 1) LBS-facilitated (i.e. 
differential regulation between 17K and 17K + -ACA treatments), 2) rationalization for a role 
in atherosclerosis, and 3) no differential regulation between vehicle and vehicle + -ACA 
treatments. For these genes, we compared expression in response to Lp(a), 17K, and 17K + -
ACA; these data are shown in Figure 3.13. These genes have ascribed functions in 
inflammatory mediation, immune cell chemotaxis, cell-cell adhesion, and modulation of the 
extracellular matrix. 
4.5.1 LBS-facilitated effects in inflammation and chemotaxis: roles for 
CCL4L1, CCL15, CCL19, CXCL14, IL1A, IL6, IL12B, IL23A, 
TNFAIP2, TNFAIP2, and TNFSF15 
The genes listed in the heading have established roles in modulating the function and activity 
of the immune system. Members of the CC and CXC chemokine families largely serve as 
immune cell chemoattractants and induce convergence of various leukocyte subtypes at sites 
of injury215,216. Interleukins serve a wide variety of functions, each individual member exerting 
numerous physiological effects; however, the interleukins we found to be differentially 
expressed – interleukins 1, 6, 12, and 23 – are all considered to be pro-inflammatory in 
nature215. The LBS-facilitated up-regulation of these interleukins, and of the CC and CXC 
chemokines, supports a role for the function of the apo(a) KIV10 domain in the inflammatory 
properties of apo(a)/Lp(a). The TNF-induced proteins (TNFAIP2 and TNFAIP6) have anti-
inflammatory roles217,218, so the increased expression of these factors that we have reported 
may indicate protective autoregulation of the inflammatory response evoked in response to 
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apo(a). Finally, TNF superfamily member 15 (TNFSF15) is the only known ligand for death 
receptor 3219, suggesting a potential role for apo(a)/Lp(a) in T cell apoptosis. Additionally, high 
expression of TNFSF15 has been demonstrated to correlate positively with prevalence of CAD 
in humans220. Overall, these findings support the proposed identity of Lp(a) as a potent pro-
inflammatory stimulus in the vasculature, and suggest that the lysine binding properties of 
apo(a), along with its covalently-bound oxPL have roles in mediating this effect.  
4.5.2 LBS-facilitated effects in cell-cell adhesion and extravasation: 
roles for CD302, JAML, and SELE 
The adhesion of leukocytes to the endothelial lining is a critical step in the development of 
atherosclerotic lesions, facilitating leukocyte extravasation from the plasma into the intimal 
compartment of the blood vessel216. We demonstrate lysine binding-dependent repression of 
CD302 and Junctional Adhesion Molecule-Like (JAML) expression in response to apo(a), but 
increased expression of E-selectin (SELE). At first glance, the down-regulation of cell-
adhesion molecules may seem counterintuitive, but when the cell-specific expression of these 
proteins is considered, these results are logical. CD302 and JAML are naturally found on 
monocytes and macrophages, with evidence supporting roles for these receptors in the 
adhesion, migration, and extravasation of these cells221,222. In this context, one must consider 
that we have exposed macrophage-like cells to a type of inflammatory stimulus that would 
normally be encountered only after atherosclerotic plaque invasion. It is therefore 
understandable that the expression of cell-adhesion molecules is repressed in response, as such 
factors would serve no further function at this stage. On the other hand, the massive up-
regulation of E-selectin expression we have observed, while not relevant in leukocytes, 
suggests that apo(a)/Lp(a) may up-regulate E-selectin in endothelial cells by a similar 
mechanism. Indeed, it has been shown previously that Lp(a) stimulates E-selectin production 
in human coronary artery endothelial cells223. Our finding that SELE expression in 
macrophage-like cells is enhanced when comparing 17K to 17K + -ACA (but not absent in 
the 17K + -ACA treatment) allows us to speculate that this effect is partially, but not fully 
LBS-facilitated in endothelial cells as well. 
 
85 
 
4.5.3 LBS-facilitated effects in extracellular matrix remodeling: roles 
for HAS2 and MMP13 
The simultaneous up-regulation of hyaluronan synthase 2 (HS2; HAS2) and repression of 
matrix metallopeptidase 13 (collagenase 3, MMP13) indicates a net increase of hyaluronic acid 
deposition in the atherosclerotic plaque microenvironment. Hyaluronic acid has been identified 
as a component of human atherosclerotic plaques at all stages of lesion development224,225. 
Hyaluronic acid deposition may serve to facilitate macrophage recruitment, as it has been 
demonstrated that macrophages bind hyaluronic acid on the endothelial surface and within the 
arterial wall in a CD44-mediated fashion226,227. While invasive immune cells such as 
macrophages act to degrade ECM in order to migrate into the atherosclerotic lesion, rather than 
to secrete ECM, it should be considered that apo(a)/Lp(a) exposure may elicit a HS2-mediated 
secretory response in other nearby vascular cells, such as SMCs. The relevance of HAS2 
expression in atherosclerosis is clear: hyaluronic acid is an ECM component found in human 
atherosclerotic plaques224,225, and has established implications in inflammatory modulation and 
promotion of cell migration228,229.  
In the context of inflammatory modulation, apo(a) has been shown previously to up-regulate 
COX-2 (PTGS2) expression in endothelial cells, an effect that was demonstrated to require 
KIV10 sLBS function110. COX-2 mediates the conversion of arachidonic acid to prostaglandin 
H2, a precursor for prostaglandin E2 (PGE2), which has been shown to be abundant in human 
atherosclerotic plaques230,231. In addition to its effects as an inflammatory mediator, PGE2 has 
been found to induce HAS2 expression in human SMCs232. Taken together, these findings 
comprise a multi-step, LBS-facilitated pathway through which apo(a)/Lp(a) may elicit 1) 
increased prostaglandin synthesis, and 2) increased HAS2 expression/hyaluronic acid 
synthesis, within atherosclerotic plaques. This does not directly address implications of 
increased HAS2 expression in THP-1 macrophages treated with apo(a)/Lp(a), but proposes a 
mechanism by which the same effect may be evoked in SMCs as a consequence of apo(a)/Lp(a) 
exposure.  
In the context of cell migration, hyaluronic acid has been demonstrated to decrease PDGF-
induced SMC proliferation and increase PDGF-induced SMC migration in cultured human 
pulmonary vascular SMCs, suggesting a role for hyaluronic acid in fibrous cap formation224. 
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4.6 Study limitations and future directions 
The greatest limiting factor of this work was our inability to generate an apo(a) species with 
intact KIV10 lysine binding function that also lacked the covalently bound oxPL. While we 
have shown that KIV10 His33-substituted apo(a) species are able to be translated, the 
intracellular retention of such variants within the ER prevented their purification and functional 
characterization as part of this work. Similarly, the intracellular retention we have shown for 
KIV10 Arg10-substituted apo(a) species has limited our ability to functionally characterize 
these variants in the same way. While we believe that the in vitro findings we have shown are 
translatable to in vivo systems, we must consider that this is not always the case, and that our 
use of in vitro systems is an inherent limitation of our work. However, identical reports of ER-
based intracellular retention of apo(a) species has been reported in cultured primary baboon 
hepatocytes195, suggesting that our findings are indeed a true representation of the secretory 
pathway in vivo. In order to further demonstrate the ER-based intracellular retention of R10Q-
substituted apo(a), we plan to assess organelle co-localization of full-length wildtype and 
R10Q apo(a) variants in both HEK293 and HepG2 cells, in a similar fashion to that shown in 
Section 3.1.3. This approach will add a second dimension to the immunoblot data shown in 
Section 3.1.5, by demonstrating intracellular retention of R10Q-substituted apo(a) using 
confocal immunofluorescence microscopy. In future investigations of the KIV10 R10Q 
substitution, mass spectrometry of Lp(a) isolated from the plasma of rs776662773 carriers 
should demonstrate the absence or presence of apo(a) species containing this substitution in 
humans, thereby supporting or refuting our assertion that this polymorphism represents a null 
LPA allele. Further, an assessment of the potential contribution of chronically ER-retained 
apo(a) in hepatocytes to fatty liver-related pathologies should be conducted using an 
experimental approach like the one proposed to address this in Section 4.2.  
Our finding that the KIV10 M64T substitution enriches oxPL abundance was demonstrated in 
the truncated KIV10KV construct, which is not a physiologically relevant apo(a) species. To 
date, however, the characteristics of the structural components of KIV10 (oxPL, sLBS) have 
been translatable from KIV10KV to full-size apo(a) variants13,190. While this strongly implies 
that M64T-mediated oxPL enrichment will be present in full-size apo(a) species, this must be 
confirmed before we can propose its relevance with respect to human physiology. If this effect 
is confirmed in recombinant variants of naturally-occurring apo(a) isoforms (e.g. 14K, 17K), 
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future studies may aim to retrospectively analyze previous population studies in order to 
determine whether the rs1801693 polymorphism (KIV10 T64M; recall that Thr64 is the major 
allele in the population) is associated with reduced CVD risk and/or mortality. An additional 
approach to directly assess the functional effects of covalent oxPL enrichment will be the use 
of Met64 and Thr64 apo(a) variants, in parallel, for in vitro experiments using the methods 
described in Section 2.10. 
4.7 Summary and conclusions 
In summary, we have shown that the KIV10 domain is a highly sensitive structural component 
of apo(a) with important implications in the processing and secretion of apo(a) itself, as well 
as a critical role in the facilitation of apo(a)-induced pro-atherogenic effects in vascular cell 
types. 
We have shown that single substitutions of either Arg10 or His33 in KIV10 are sufficient to 
cause intracellular retention of apo(a) species containing these substitutions, and have provided 
evidence that this retention occurs in the ER, in agreement with the findings of a previous 
group. The R10Q substitution is the result of a rare, naturally occurring SNP (rs776667223) in 
the LPA gene, with a prevalence of 0.01-0.03% in the human population. Since previously 
established LPA null alleles result in premature truncation of the encoded apo(a) species, we 
propose that this SNP represents a novel type of null allele for the LPA gene, derived from a 
single amino acid substitution (rather than a nonsense mutation). The implications of this 
finding are relevant only to the small proportion of the human population who are rs776667223 
carriers, but we hypothesize that this SNP may correlate with decreased plasma Lp(a) 
concentration, decreased CVD risk, and/or increased prevalence of fatty liver. 
Using the truncated KIV10KV apo(a) variant, we have shown that the identity of the residue at 
KIV10 position 64 is able to influence the degree of oxPL modification the protein undergoes. 
This, in itself, is a novel finding, as this is the first demonstration of oxPL-positive apo(a) 
species that differ in the relative extent of oxPL modification. The major and minor LPA alleles 
contain KIV10 Thr64 and Met64, respectively, with the threonine-containing allele found at 
approximately twice the prevalence as the methionine-containing allele in the human 
population. We have demonstrated that the Thr64 variant of KIV10KV contains approximately 
2.8 times the covalent oxPL per mass quantity of protein than the Met64 variant does. Based 
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on the roles which have been proposed for oxPLs in atherosclerosis, along with the atherogenic 
gene regulation effects we have shown to be oxPL-dependent in THP-1 macrophages, we 
hypothesize that Thr64-containing apo(a) species may be associated with increased CVD risk 
compared to Met64-containing species.  
The complex structure-function relationships of apo(a) KIV10 are exemplified by the gene 
regulation effects we have shown in THP-1 macrophages that are contingent on the lysine 
binding ability of apo(a), as well as those that are exclusively due to the presence of the 
covalently bound oxPL. Our overall understanding of the results presented herein is that apo(a) 
elicits a wide variety of LBS-facilitated gene regulatory effects in THP-1 macrophages, 
implicating both the KIV10 sLBS and covalent oxPL in this process. We have demonstrated 
that apo(a)/Lp(a) have the potential to drastically alter the microenvironment of atherosclerotic 
plaques by altering the expression of genes related to leukocyte convergence/chemotaxis, cell-
adhesion, pro-inflammatory signaling, and ECM deposition. 
In conclusion, the KIV10 domain is a key domain in apo(a) with complex structure-function 
relationships. We have shown that single-residue substitutions in the primary sequence of 
KIV10 can alter the extent to which this domain is modified covalently with oxPLs, or even 
prevent the secretion of apo(a) entirely. We have also shown that sub-structures of KIV10, 
namely the sLBS and oxPL, are strongly implicated in the pathogenicity of apo(a)/Lp(a). Taken 
together, these findings support our hypotheses and supply evidence indicating critical roles 
for the structure and function of the apo(a) KIV10 domain in the pathologies associated with 
Lp(a) in vivo. 
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